id
stringlengths 36
36
| title
stringlengths 0
391
| funder
stringclasses 64
values | beneficiary
stringlengths 3
1.44k
| source_id
stringlengths 0
41
| abstract
stringlengths 6
4.76k
| funding_scheme
stringclasses 403
values | label
class label 8
classes |
|---|---|---|---|---|---|---|---|
gen_2941f476ef1c51fe5dd7f568fb36f365 | Developing a percutaneously permanent implantable left ventricular assist device to treat heart failure | Innovate UK | Cardiology Devices Ltd | HRCS22_21298 | Cardiovascular disease is the most common cause of death in the UK. After a heart attack, the heart is weaker, and struggles to pump blood around the body. This causes less blood to get to the kidneys and brain and whilst patients can take medications to help, they cannot make the heart return to normal, and sadly approximately 60,000 people in the UK per year still die from heart failure. This innovation is a device which cardiologists can insert relatively quickly and easily and works with the heart to improve the blood supply to the organs, and reduce the workload of the heart. It has the potential to either bridge patients to a heart transplant, or even for patients to live with for many years. This gives the potential for the heart to recover, or for them to live with for the rest of their lives, essentially curing them of end stage heart failure. | Missing/Incomplete | 0business_rnd_innovation
|
gen_3079d1721a68b7b5870243dfd8ab859f | CELL AND GENE THERAPY CATAPULT CORE DELIVERY PROGRAMME | Innovate UK | Cell Therapy Catapult Limited | HRCS22_21305 | Awaiting Public Project Summary | Infrastructure | 7research_infrastructure
|
gen_3d29d070a1adeb990354a86ff3aa208f | GFA in relation to the Acquisition, Development and Operation of the Cell and Gene Therapy Catapult Manufacturing Innovation Centre | Innovate UK | Cell Therapy Catapult Limited | HRCS22_21306 | Awaiting Public Project Summary | Infrastructure | 7research_infrastructure
|
gen_b6e1f7bc9efd194d023cb8e1b3b80c3d | ElderEye - Development of a circadian lighting and healthcare monitoring system | Innovate UK | Circadian Lighting Limited | HRCS22_21319 | Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details. | Missing/Incomplete | 0business_rnd_innovation
|
gen_a59ba7944b3c37e367736516ece1073a | Scaling up synthesis of Colorado State University's fluoroalkylphosphines | Innovate UK | Cortex Organics Limited | HRCS22_21337 | This feasibility project represents an opportunity to seed a new partnership whereby Cortex Organics Ltd could become the commercial producer of new, patent-pending chemicals from Colorado State University. These chemicals have potential uses in drug discovery and agrochemical R&D, and researchers around the world are potentially interested in investigating their properties, if the chemicals can be supplied in useful quantities on a commercially viable basis. If successful in this feasibility project and ultimately in discovering new ways to produce these chemicals on a commercially viable basis, then Cortex Organics could become a global supplier or the exclusive global supplier of these chemicals to R&D labs. If the chemicals are found to have applications in novel drugs or agrochemical, then Cortex Organics could find itself in possession of critical intellectual property used in large-scale production. This would open up new revenue opportunities such as licensing synthesis methodologies or subcontracting production. Professor Andrew McNally and his team at Colorado State University recently developed a set of bench-stable fluoroalkylphosphines that directly convert C--H bonds (in drug-like molecules) into fluoroalkyl derivatives \[Zhang et al., Nature, April 2021\]. This is important in the context of an overall industry trend toward new drug candidates that contain trifluoromethyl (CF3) and difluoromethyl (CF2H) groups. Fluoroalkylphosphines are particularly useful in manufacturing these new drug candidates and offer the advantage that they can be applied late in the drug candidate synthesis process. Cortex reached out to Prof. McNally to put itself forward as a commercial partner for the first phase of commercial exploitation of Prof. McNally's work: the production of \>50g batch quantities for commercial sale to organic chemistry researchers. Cortex Organics are experts in developing new synthesis methodologies for the production of chemicals, with over 100 innovative new synthesis methods discovered during the company's short history. Cortex already offers various chemicals for commercial sale through its website, and it has developed and sold synthesis processes to other manufacturers. The company is well-placed to help exploit these exciting new developments in fluoroalkylphosphine reagents. This feasibility study will provide essential breathing space allowing the Cortex team to investigate and assess the possibilities around entering this market and inject real value and momentum into the budding dialogue between Cortex and Colorado State University. | Missing/Incomplete | 0business_rnd_innovation
|
gen_896a164f7a2cb718ab97b1670fce1bfa | Cricketqube - Healthy Ageing for South Asians Through Cricket | Innovate UK | Cricketqube Limited | HRCS22_21341 | Cricketqube was established in 2020 with the mission of making cricket accessible for everyone, anytime and anywhere. Within a short frame of time, we have grown to offer our unique service of backyard cricket (BYC) to schools, corporates and families. **Backyard Cricket** BYC reimagines cricket with our all-weather backyard events complete with wheelie bins and clotheslines, taking our players to their childhood. Our events are focused on getting fit and having fun at the same time. **Target Market** With this project, we take BYC to one of the communities it needs the most - people from the South Asian ethnicity. Here BYC would take on the mantle as a one-stop solution for healthy ageing in this community. We especially focus on the South Asian women for whom healthy ageing and an active lifestyle are virtually impossible to aspire. **Why South Asians?** There is a notable absence of social and governmental support for South Asians to engage in regular physical activity. The mental health issues of its members are often not taken seriously either. **How does BYC Benefit South Asians?** Cricketqube would develop a medical protocol - complete with physical and mental health guidelines - in order to adapt BYC to the older adults in the community. This protocol would be prepared by experts with lived experience in the community. We would then design a delivery plan for the adapted BYC among the target audience. Crucially, this plan would then be validated by the community leaders and learning from them would help in creating the final delivery plan. A full financial budget, forecast and marketing plan would complete this phase of the project. We would then pilot BYC in two locations in the UK - one of them exclusively for women in the community. Soon after the end of the study, BYC would ready a national roll-out through our franchises. **Key Points** * The first company to offer a culturally fit and integrated healthy ageing solution for the South Asians in the UK. * Introduce mental health professionals at our events to help South Asian women to open up and seek help about their mental health - often a taboo subject in the community * Introduction of a women-led steering group for BYC events for women - agency back to the women. * Accessible, affordable and fun events. * We actively collaborate with key stakeholders including community leaders, cricket bodies and healthy ageing specialists. | Missing/Incomplete | 0business_rnd_innovation
|
gen_0e075769fd07f53da99c841c748476ca | HEART (Health Excellence with Ai and Real-time Targets) | Innovate UK | Disability Intelligence Limited | HRCS22_21371 | Preventing, reducing and managing lifestyle disease is challenging for individuals, friends/family and society. Disability Intelligence proposes a platform to help users change their lifestyle to give them a better chance of preventing lifestyle disease occurring and reducing the associated socio-economic impacts their friends/family and society. This project will work with highly-specialised user-experience and technical development organisations to deeply research different user and associated challenges, causes and impacts. The technical and commercial feasibility of this lifestyle disease prevention, reduction, management platform will be established. | Missing/Incomplete | 0business_rnd_innovation
|
gen_63ad5ad26e5ceff5bd792e79e852076e | DocMe: a novel consumer app to measure blood pressure from a face video for the remote monitoring and management of cardiovascular health | Innovate UK | Docme Technologies Ltd | HRCS22_21374 | Our mission is to reduce the blood pressure (BP) of the nation. High BP, also called hypertension, is a condition which can be controlled to reduce the risk of a heart attack, stroke or other cardiovascular (CVS) diseases. According to the NHS, in the UK, there are about five million adults (one in every nine) who have high BP without even knowing it, since high BP itself rarely causes symptoms. The British Heart Foundation estimates that high BP causes over 50% of heart attacks and strokes. Therefore, a convenient and cost-efficient BP screening tool is essential to combat this silent killer. We propose a market-first consumer mobile app that can measure BP by taking a selfie. By leveraging the remote photoplethysmography (rPPG) technology, DocMe can measure BP reliably without the need for any additional hardware devices or wearables. Our proposed solution offers a radically new approach that can facilitate more proactive, personalised and cost-saving treatment of high BP and can potentially prevent more severe health consequences such as heart attacks or strokes, vascular dementia and chronic kidney disease. The ubiquitousness of smartphones and the convenience of selfie technology make DocMe BP measurements more accessible and much cheaper than the current alternative. Once available on the App Store, you will be able to check your basic vital signs up to 5 times a week for free, or upgrade to DocMe premium for £5/month for unlimited measurements and in-depth analytics of your cardiovascular health. | Missing/Incomplete | 0business_rnd_innovation
|
gen_a4122e5a32696db9fa6680eeb8d9e07a | The Safer Prescription of Opioids Tool USA Market feasibility study | Innovate UK | Doctor Flint Limited | HRCS22_21375 | SPOT - The Safer Prescription of Opioids Tool is a novel digital health platform, distributed as software as a service, which is proven to significantly improve the confidence of opioid prescribing and adherence to best practice guidelines. SPOT has been featured by the BBC and is one of SDI's top 12 Digital Health innovations to watch in 2020\. SPOT has been included in the Scottish Government's Coronavirus 19 palliative care response toolkit. Following a recent IUK project, SPOT has partnered with a UK and European-based professional publishing distributor, Class Professional Publishing. As of April 2021, SPOT is now available Europe-wide on their Salesforce platform, complemented with first-line sales and technical support. Building on specific contacts engendered over the last two years, our progress in the UK and European markets, and an increase in momentum for digital health from the COVID-19 pandemic, we seek to carry out a feasibility study with potential commercial partners in the USA who have already expressed interest in SPOT. | Missing/Incomplete | 0business_rnd_innovation
|
gen_154d01b908d740023f1e8cc7df225fad | Predictive modelling of wellbeing in high growth companies | Innovate UK | Evolyst Limited | HRCS22_21416 | Lumien is a wellbeing analytics platform that measures where individuals & populations struggle with their mental and physical wellbeing at home and at work and offers support to help individuals, managers and organisations understand and manage problems. We are currently using machine learning to move towards a pro-active model. Identifying when individuals or populations may begin to struggle and suggesting small adjustments to reduce the negative impact of mental wellbeing to both individuals and teams before it occurs. This project aims to improve the dimensionality of our data, therefore allowing more targeted analysis of mental wellbeing across populations. | Missing/Incomplete | 0business_rnd_innovation
|
gen_f44e14546bc9eb6da2836452ef6d4e3b | Accelerated Development of “bitbaby” | Innovate UK | Fetal Monitoring Limited | HRCS22_21431 | Fetal movement is a measure of normal fetal development and wellbeing. Reduced fetal movements can be an indication of fetal compromise leading to poor outcomes. Women are advised to be aware of their baby's movements and contact their maternity unit if these movements change or reduce. However, research has shown that women don't fully understand what they should be checking for and so doubt themselves, leading to increased stress/anxiety, and delays before seeking advice for reduced movements. "bitbaby" is a passive, at-home fetal movements monitoring system, consisting of a wearable band and a mobile application. An array of accelerometers are worn in the fabric band and can detect fetal movements via vibrations through the mother's abdomen. Movement data is then presented to the mother in daily/weekly charts. A mood tracker is also provided, allowing mothers to enter daily mood logs and monitor their mental wellbeing during pregnancy on weekly charts. The aim of this is to encourage women to be more aware of their mental wellbeing during their pregnancy and be encouraged to seek advice if they notice their mood is persistently low over a period of time. The project is designed to help accelerate development of the bitbaby system, through funding of data collection activities/studys, product development, regulatory support and intellectual property searches. Following the project, the system will be ready for final clinical investigation and submission to a notified body for conformity assessment as a class IIa medical device. Providing this to the public will improve mental health for mothers during pregnancy, and reduce associated costs to the NHS related to unnecessary admissions/interventions and poor outcomes following reduced fetal movements. | Missing/Incomplete | 0business_rnd_innovation
|
gen_982f66969cf5f572ebc20f471714f149 | Butterfly Indoor Air Quality System integration with Building Management Systems | Innovate UK | Flutterlab Ltd | HRCS22_21436 | The unifying element for analysis of human health and wellbeing and environmental sustainability lies in the air that we breathe. Health and Sustainability have previously been conflicted in the built environment where we spend 90% of our lives, because the former requires maximised introduction of fresh air whereas the latter requires maximised recirculation of existing air. The scale of the problem is most prominently highlighted through the emergence of Sick Building Syndrome (SBS). 1/3rd of industrialised country building stock is prone to SBS (WHO). Numerous neurotoxic and carcinogenic pollutants concentrated in commercial buildings induce headaches, eye, nose and throat irritation, fatigue and difficulty concentrating, alongside respiratory and cardiovascular diseases. This is a worsening trend, potentially causing 4m deaths p.a. (International WELL Building Institute (IWBI)). Existing Indoor Air Quality (IAQ) monitors do not provide the required quality of information to allow the Building Management Services industry to make this an intelligent process. Existing monitors regularly claim this facility, but cannot demonstrate it sufficiently to allow their technology to be embedded within critical infrastructure systems. Butterfly is developing a suite of devices which measure IAQ to an unparalleled level of accuracy. We have a patented LaminAIR flow technology, which allows us to constantly measure free gas around the room preventing re-circulated or stagnant air corrupting results (an industry-wide limitation). Our precision is so good it uniquely enables early trend detection and allows issue resolution in advance. We have gained traction with market leaders regarding integration within their systems. This project is to develop bespoke connectivity and data infrastructure and then trial this at 6 locations within Imperial College London's city-centre campus (they will independently validate results). Mutual Letters-of-Intent with joint-technology development commitment have been exchanged, including undertakings with Blueair-Unilever Sweden, Halton Group Finland and Imperial College London where trials will be undertaken and validation established. | Missing/Incomplete | 0business_rnd_innovation
|
gen_72cca2d5dad768ebfd88219e8cde83fa | Menopause Reality | Innovate UK | Forward Slash Films Ltd | HRCS22_21437 | Menopause Reality is a project that will help employers retain their female workforce, improve professional training for healthcare providers, and directly support women going through the menopause, improving their health and economic outcomes. The project will use deeply engaging immersive technology, to empathise, educate and improve understanding of the menopause through absorbing content & novel delivery. The project will produce a series of 360films, each sharing a genuine experience of the menopause - their own Menopause Reality. The immersive format allows for very direct and intimate sharing of experiences, and ensures that audiences can make strong connections which are shown to deliver powerful influence and behavioural/attitudinal change. Menopause Reality will use immersive technology to deliver behavioural and cultural change that will improve health and economic outcomes for women, their families and employers. VR technology is still in early stages of adoption for most industries, and our approach, which uses behavioural psychology research along with authentic narrative storytelling, ensures that this innovation is applied and fully exploited to deliver tangible health outcomes, and business and economic growth. | Missing/Incomplete | 0business_rnd_innovation
|
gen_5aca1335046025d5128bc963c348e4b7 | Novel, Accessible zero-emissions vehicle-format for enabling self-care and independence for mobility-limited persons. | Innovate UK | Forzuna-Navigation Ltd | HRCS22_21438 | Development of a new micromobility vehicle-format, which introduces Accessibility to the sector. By 'blurring the lines' between what is considered an 'able-bodied' persons choice of fashionable, convenient transport, and what is a powered-wheelchair, the stigma of having to use an 'invalid carriage' is broken down, enabling more people to confidently use assistive-mobility. A 2018 NHS poll 'Why don't people use their mobility aids?' (studying the high abandonment rates of provided-chairs - costing the NHS an estimated £16M/yr), found the 'image' and weight-inconvenience (lack of independence) were the two top-ranked factors. This new vehicle-format looks nothing like a wheelchair or mobility-scooter, it carries the user at adult eye-level while travelling, but can 'squat down' to create a sturdy seat when parked. Its hands-free control, unconventional form-factor and (customisable) styling, plus its capability to negotiate difficult terrain (kerbs, gravel, snow, sand etc) - and still be compact-enough to be lifted with one hand (and fit on an escalator-step), makes it far more attractive to a diverse user-group than existing micromobility options. Industry experts see it as a convenient replacement for e-scooters, because it takes up less space, doesn't fall-over, has shorter stopping-distance, and greater agility. It will be welcome on public-transit, due to it having removable (auto disconnect) battery-cassette, it's like 'bringing your own seat' (passengers don't take up stowage-space and a carriage-seat). Safety around pedestrians (and indoor use) is a problem for other personal-mobility formats; This vehicle's small footprint aids proprioceptive-judgement, its control-system simulates the natural reflexes of perambulation (weight-transfer while walking), and doesn't engage distractive cognitive resources for operating handlebars, brake-levers or joysticks (or watching for pavement-imperfections). The rider has more 'headspace' consideration for those around them (unlike e-scooters, which need concentration to maintain speed adequate to remain stable). Its new behaviour-algorithm provides ability to balance while stationary (the rider doesn't have to do the balancing), the dynamic-height chassis enables easy transfer, and safe mount/dismount, unparalleled by any of its competitors. The new vehicle is less than half the price, and less than 1/3rd the weight of current state-of-the-art. The UK's leading mobility-tech team at ORLAU, support this product as something which will give millions of perambulatory, and fatigue ailed persons, a viable alternative to using the NHS as default choice for solving their mobility problems. This product makes self-care a viable choice, in its functionality, affordability and overcoming the self-worth issues that come with having to use conventional mobility-aids. | Missing/Incomplete | 0business_rnd_innovation
|
gen_a5925678e6b3fc2927937d3fa05ff20a | Advancing the technology readiness level of rapid additive manufacturing microfluidic technology for personalised medicine and organ-on-a-chip applications. | Innovate UK | Frontier Space Technologies Ltd | HRCS22_21443 | Frontier Space Technologies enable biomedical and pharmaceutical research in space for the benefit of life science applications on Earth. In this context, our main product is Space Lab, a miniaturized lab is capable of performing a wide variety of biomedical research activities in space. Each Space Lab is fully autonomous, remotely controlled, and approximately the size of a shoe box. It has a range of scientific hardware onboard including a 32 multi-chambered sample disc, a microscope, a microfluidics system and temperature, pressure and atmospheric composition sensors. Performing this kind of research has numerous benefits thanks to the natural habitat present in space, mainly microgravity and high radiation. This means that scientific research in the fields of personalized medicine, organ-on-a-chip, drug development, organ and tissue 3D printing, stem cell study, and protein crystallization is greatly facilitated when performed in space. The same technology can be brought down to Earth as a diagnostic tool for self-driven health care and de-centralised health care The outcome of this research will initially benefit Earth and terrestrial applications. Within the Innovate UK project, Frontier is determined to perform a 6 months research period aimed at advancing the TRL of the hardware needed for personalised medicine and organ-on-a-chip, using a biocompatible 3D printer. In addition to this, this project will also allow Frontier to access new markets related to these field and funding. | Missing/Incomplete | 0business_rnd_innovation
|
gen_507ef083efdfa498338f4054d99323a2 | ISCF Supported whole genome sequencing in cancer trials | Innovate UK | Genomics England Limited | HRCS22_21458 | Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details. | Infrastructure | 7research_infrastructure
|
gen_101fca45eba437cbe21969095d552462 | Developing Airglove V2 Technology for Peripheral Arterial Disease Healthcare (DATPADH) | Innovate UK | Green Cross Medico Limited | HRCS22_21469 | **Public description** Green Cross Medico, based in Hamilton, Scotland, applied for a Fast Start Innovation grant from Innovate UK to assist with the development of its unique and patented Airglove technology for peripheral arterial disease (PAD). The company has spent over five years developing Airglove Arm, which delivers warm-air treatment to act as a thermo-vasodilator. The first generation use of Airglove was to improve Difficult Intravenous Access (DIVA) cannulation. In the UK alone, over 32M cannulations take place each year and nearly one third require more than one attempt. Airglove facilitates DIVA cannulation, taking just 3 minutes to dilate the vein for improved access and is used in many clinical areas such as oncology, haematology, apheresis, infusion, PET Scans, nuclear medicine, plasma exchange therapy and radiology with proven 87.5% 1st time cannulation success in trials. "Airglove has helped out with some really difficult cases where we would sometimes have to move to central lines" Nurse/Practitioner at Addenbrooke's Hospital, Cambridge Having worked closely with NHS Innovation South East we were approached by Professor Philip Stather to re-develop the technology for PAD. An awarded grant will assist the company to develop Airglove Leg for self-management home therapy of patients with PAD. 200M people globally suffer with PAD, which is caused by a build-up of fatty deposits their leg arteries. It can result in leg pain (intermittent claudication) and reduced mobility. Sometimes PAD can progress to critical limb ischaemia and, worst case scenario, leg amputation with a 20% mortality within 6 months of diagnosis. The IUK Fast Start grant will fund the development of a new generation of internationally-compatible Airglove device for the LEG use with battery pack, disposable gloves, positioning the device for UK/International use. Airglove LEG will improve patient outcomes and quality of life including their carers. It will also provide clinicians with an effective tool for the self-management home therapy of PAD if supervised exercise therapy (SET) is not available in their hospital trust or patients are not able to travel due to mobility. Airglove will reduce costs for the NHS and other healthcare payers plus help increase the flow-through of patients helping to tackle the NHS backlog as outlined in the Health Secretary £36billion investment of "New treatments and diagnostic and streamlined surgical methods believed to result in more patients being seen to quickly and safely". Airglove will also create additional manufacturing, exports and employment in the UK. | Missing/Incomplete | 0business_rnd_innovation
|
gen_f47c86cf01231eda73eac040585bd694 | hangAIR - a novel wellness pod, enhances a home treatment value of existing medical interventions | Innovate UK | Hangair Global Ltd | HRCS22_21474 | hangAIR is the world's-first forward incliner designed for optimal and time-effective sleep and recuperation, holding a person in the tripod/forward-inclining position induced with a rocking motion, aiming to help millions of people who suffer from stress, anxiety, sleep and respiration disorders. hangAIR addresses the market-gap for a cost-effective therapeutic solution that can be deployed at-home, office, airport. The value of hangAIR is in reducing the "work-of-breathing" (the energy expended to breathe). Sleeping-resting in tripod position, induced with the rocking, enables automatic abdominal-deep breathing that improves oxygenation and detoxification of the lungs, helps control the nervous system and encourages the body to relax without making conscious effort. hangAIR aims to provide a significant impact that will reduce healthcare costs, improve health outcomes for millions of people in the comfort of their home. | Missing/Incomplete | 0business_rnd_innovation
|
gen_8be205021afce478585f3e370a393d95 | Smart headband for brain health management in school and grassroots sport | Innovate UK | Headx Limited | HRCS22_21477 | Concussion, Traumatic Brain Injury (TBI) and Chronic Traumatic Encephalopathy (CTE) is a growing issue in contact sport, with significant increase in former players being diagnosed with early onset dementia. This is a growing concern for players, coaches, sport clubs, schools and parents. The Digital, Culture, Media and Sport Committee produced a report in July 2021 highlighting these concerns. HeadX is developing a Smart Headband specifically designed to support players, teachers, coaches and parents in ensuring safe participation in grassroots contact sport. The smart headband is design a number of accelerometers and gyroscopes to accurately capture a players head movement 100 times a second. To date they have developed low volume, proof of concept prototypes that have been trialled at a local Gloucestershire Rugby club. The evidence from these trials provided excellent insight into the learning that can be gained from wearables and data analytics in developing our understanding of contact sports and brain health. This project provides an excellent opportunity to help teachers and coaches to "Recognise and Remove" any player that incurred brain trauma. It also help coach players to improve their technique and learn from objective data. Innovate UK grant funding will allow the team to further develop their prototype towards a Law 4 Innovation trial with World Rugby. The funding will significantly improve the design, size and comfort of the wearable device alongside developing the software to improve accessibility in a busy school / rugby club environment. The software development will mean that a club can quickly download, analyse and learn from completed sessions. | Missing/Incomplete | 0business_rnd_innovation
|
gen_382e0f65e3458d87997b98d100a61346 | Falls Prevent | Innovate UK | Hip Impact Protection Ltd | HRCS22_21496 | This ground-breaking Falls Prevent application aims to reduce the numbers of falls and fractures by the elderly, worldwide, thereby extending the lives of hundreds of millions of those suffering from osteoporosis who have a tendency to fall, for whatever reason -- and there are over 400 such reasons! The project will radically improve the quality of lives of those in the category, of whom at least 50% have a distinct, and often well-justified, fear of falling. The cost savings are measured in £billions and there are no possible side effects, nor regulatory barriers. This project includes a trial in a company that manages 26 large care homes in the South of England, with half-a-dozen users of the Falls Prevent product in each. It will then be marketed to the wider community of fallers with osteoporosis, living in their own homes, as well as to other care home groups and Local Authorities and ICSs. There are over 500,000 falls serious enough to warrant admission at A&E every year in the UK alone, resulting in almost 100,000 hip fractures, as well as limb and vertebrae fractures. The costs in the UK for falls and fractures have been calculated at over £4.5bn. a year, representing an enormous burden on the NHS, and with an ageing population, the numbers are increasing year-on-year. The costs in the US are over $50bn. a year. Many other approaches have been tried for reducing the numbers of falls, but all have failed. There is no falls database anywhere in the world because it has not hitherto been possible to record all falls accurately and most falls go unrecorded for a variety of reasons, so there was no point in filling such a database with spurious data. AI will be the key to mining the vast quantities of data involved, for predictors. All the devices have been tried and tested in many countries over a number of years and have proved to be completely acceptable to users of whatever age. They are very simple to install and use and unnoticeable when being worn by the elderly 24/7, including in the bath, shower and in bed. No other similar device exists and the idea has been patented by the company in the UK, USA and in Europe. Distributors for the system have been signed up worldwide and it will be available on Amazon, as are most of its elements already. | Missing/Incomplete | 0business_rnd_innovation
|
gen_5fa45b897cf4cf3ea3da070597d481cd | Development of a neurofeedback wearable device to measure mental state | Innovate UK | Huru Ltd | HRCS22_21500 | Public attitudes towards mental health are improving, and there is a growing commitment among communities, workplaces, schools and within government to change the way we think about it. Influential ambassadors such as Princes William and Harry have worked to normalise talking about mental health. The Five Year Forward View for Mental Health, a landmark moment, published in February 2016, set out a clear and unarguable agenda for the reform of mental health care in the UK. We believe we can help this agenda, improving the outcomes and wellbeing but also tackling the wider costs of mental ill health to the health service and society as a whole. Research in this area has accelerated dramatically in recent years. Neuroscience and psychology disciplines are increasingly interconnected, leading to deeper understanding of both mechanism and real word application of interventions; improving the efficiency of where and how to focus future research and treatment. Leading scientific influencers are also transforming communication of the latest research into consumer focussed protocols, shortening the cycle between discovery and widespread accessibility. Whilst the above developments are promising there is a need to support those with mental health conditions today. One in four adults experiences at least one diagnosable mental health problem in any given year. People in all walks of life can be affected, including new mothers, children, teenagers, adults and older people. Mental health problems represent the largest single cause of disability in the UK. The cost to the economy is estimated at £118 billion a year -- roughly the cost of the entire NHS. As a society we are more stressed than every before, a study in 2018 by the mental health foundation found that 74% of UK adults have felt so stressed they felt overwhelmed or unable to cope in the past year. We want to support these individuals with personalised brain health data that can help them to achieve better overall mental health. We are developing a neurofeedback device and associated algorithms that provides real time and longitudinal insight into various aspects of a persons cognitive function. The data provides the user (and/or care team) with insight into the effect of the user's activities on cognitive function and/or long-term brain health. This will open up self-care through personalised insights into the things that help most and research into the long term impact of lifestyle factors on brain health in the general population. | Missing/Incomplete | 0business_rnd_innovation
|
gen_6fe3c319d68d013d5f16a7b2c47ffe80 | Development of a courier robotic platform for healthcare environments | Innovate UK | Ice Nine Limited | HRCS22_21503 | COVID-19 has had an affect on all our lives, but nowhere has been quite as affected as all of our healthcare settings. A great debt is owed to our healthcare providers and Ice Nine Ltd would like to say thank you! We would also like to aid our healthcare providers and offer solutions that reduce the burden of administrative tasks, such as transport of samples to the lab for testing and transport of critical medication from emergency stocks to the patient. These are all 10-15 minute round-trips that could be avoided and spent communicating with and treating patients. Autonomous robotic platforms are capable of a variety of repetitive and simple tasks and we believe are particularly appropriate for deployment in healthcare settings. The addition of a variety of obstacle avoidance and safety sensors, as well as a hermetically sealed, temperature controlled and secured container/chamber will enable the transportation of samples from patient to lab. This same device can also be used or adapted to transport critical medications from emergency stocks to doctors, nurses and patients. Or, out of hours food boxes can be delivered to patients admitted after the rounds have been completed to order food for that day. There is a huge opportunity to offer solutions that aid our healthcare providers and we are excited to be developing part of these solutions. | Missing/Incomplete | 0business_rnd_innovation
|
gen_16318aa8e1c76612e1f9ce96bbb3215d | EEN ENIW Innovate 2 Succeed — Covid 19 Fast Response | Innovate UK | Invest Northern Ireland | HRCS22_21539 | Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details. | Missing/Incomplete | 0business_rnd_innovation
|
gen_8fc60e89d1f5628f315c4ed3bb80b07f | Feasibility of developing precision medicine applications in Sri Lanka | Innovate UK | J?Na Bio Ltd | HRCS22_21546 | We are a biotech startup focused on developing tools for the biopharma and clinical communities to improve precision medicine for ethnic minorities and underrepresented populations. There is a lack of data from diverse backgrounds currently in the public domain to improve on algorithm development since most clinical and genomic datasets are derived from European populations. In this project we wish to assess the feasibility of establishing partnerships in Sri Lanka to generate novel datasets and developing software for digital health applications. | Missing/Incomplete | 0business_rnd_innovation
|
gen_72ae5c757e11d0d0746dbe163dc78bfa | S-Press - Revolutionising Rehabilitation | Innovate UK | Jt Rehab Limited | HRCS22_21553 | JT Rehab Ltd was set up by a senior physiotherapist with the aim of developing the most effective and inclusive rehabilitation devices, to help all patients achieve better outcomes after illness or injury. The S-Press is our first product. It is a portable leg strengthening device that is safe, comfortable, easy to use and provides therapeutic level, progressive strengthening. It will improve patient outcomes, shorten length of hospital stay, ease pressures on physio teams and provide more effective treatment options than are currently available in hospital and at home. | Missing/Incomplete | 0business_rnd_innovation
|
gen_689867a477b0b9dc9bb05cb3c13f3be0 | Driving Efficiency in Operating Theatre Lists - A Machine Learning Solution | Innovate UK | Koris Management Limited | HRCS22_21566 | There are millions of patients waiting for surgery on the NHS at this time. Despite this, productivity of operating lists is at an all time low. ListManager is an innovative piece of software designed to improve the performance of NHS operating theatre lists. Taking into account the needs of patients, the operating team, and hospitals, ListManager will automatically book patients and manage operating waiting lists. Using the latest technology, ListManager will learn and improve itself, becoming more efficient over time. ListManager will reduce waiting lists, reduce the cost to the taxpayer, and ultimately improve the lives of millions of patients who are waiting for an operation. | Missing/Incomplete | 0business_rnd_innovation
|
gen_279ae9d1a16d5ac36c25d055ba298329 | Development of self-administered diabetic wound healing therapy | Innovate UK | Kromix Therapeutics Ltd | HRCS22_21571 | This project involves the development of a remarkable innovation which offers a potentially transformative treatment for life-threatening skin ulcers, by instructing the body to re-engineer its own blood vessel networks to promote healing. Why do skin ulcers arise? The skin normally forms a robust and essential barrier to protect us from a myriad of harms in the environment. An ulcer forms when the skin barrier is breached and does not heal. The body's blood vessel networks are vital to successful skin healing: by conveying oxygen and nutrients via the bloodstream to the site of the ulcer or wound. The quality of those networks is therefore crucial to the success of healing. Patients with diabetes are at risk of developing a serious, potentially life- threatening type of skin ulcer -- diabetic foot ulcer (DFU) - that often results in intensive, hospital-based treatment or even limb amputation in the most severe cases (11,000 amputations per year at a cost to the NHS of nearly £1 billion). Their skin healing mechanisms are impaired through damage to blood vessels as well as to nerves that makes them more susceptible to injury. A healthy blood vessel supply to damaged skin is essential to healing. The body, in its enthusiasm to stimulate blood vessel growth as part of the healing response, may encourage too many small, ineffective blood vessel byways to be formed, without enough of the main highways that are considerably more effective at delivering the essential oxygen and nutrients for healing. This innovation centres on a new approach to wound healing with the use of a technology that has been shown to stimulate the regrowth of skin over an ulcer, by re-engineering the blood vessel networks so the main highways are favoured over the plentiful, but too often ineffective, byways. This new treatment intelligently re-engineers blood vessels to encourage healing. The technology is exciting in that it could be ready for clinical trials in DFU patients within 1 -2 years. The treatment would be easily applied as a cream to the skin by the patients themselves, keeping them out of hospital and avoiding serious life- threatening complications. If it is successful in DFU it may have wider application to other serious wounds, potentially offering enormous health benefits and savings to the health budget. | Missing/Incomplete | 0business_rnd_innovation
|
gen_88e8c43c7247089999c40dc56426e1f7 | Intelligent Digital Stethoscope for Improved Auscultation and Remote Healthcare | Innovate UK | Laennec Ai Limited | HRCS22_21578 | **Purpose:** Designing and marketing cost-effective high-end technology stethoscopes using bottom-up approach. **Problem:** Stethoscopes available in the market have undergone very little innovation. Of those, most have been developed by taking into consideration the engineer's perspective and not the user's perspective in mind. They also tend to be very expensive, especially for a medical professional from developing nations. **Solution:** After working in the medical care sector for a decade, we realized that essential clinical tools used today are technologically outdated. This led to the idea of developing cost-effective digital medical devices using high-end technology with Artificial Intelligence (AI). We aim to design our products from a user's perspective using an evidence-based Public Health tool - Health Needs Assessment (HNA). HNA is widely used in Public Health to understand the needs of the user and to improve the quality of healthcare delivered. This tool uses a bottoms-up approach to provide services that are tailor-made for the users. **Uniqueness:** We re-design and digitalise the stethoscope with four pillars in mind. They are accuracy, interoperability, intelligence, and aesthetics (user friendliness, and looks). The current stethoscope technology uses a normal microphone-based system is not smart and lacks the capability to track, store and share information. Our intelligent stethoscopes are capable of: * Interoperability (Storing and sharing information in audio and video format) * Supporting health professionals for better decisions: Integrated with Machine Learning and Artificial Intelligence All these advancements come without compromising the looks, the stethoscopes have touch screen displays with GUI interface and come with a compatible application that runs on mobile and PCs. **Green Growth strategy:** We are focused on a green growth strategy and aim to use sustainable and environmentally friendly materials. **Equality strategy**: We are committed to ensuring that equality and human rights are considered in everything we do. The market is massive. Our stethoscopes can be used by doctors, nurses, paramedics, veterinarians, and home healthcare. Sooner this tool is going to be inevitable for remote healthcare and telemedicine. The global stethoscope market size is anticipated to reach USD 826.72 million by 2028\. The global medical devices market size accounted at US$ 447.63 billion in 2019\. The Covid-19 pandemic shown us the requirement of tools for remote healthcare. Our major competitors are Littmann Eko, and ThinkLabs. We have a competitive advantage over them in terms of technology, sensors, aesthetics, algorithm and artificial intelligence, that we are using to deliver user requirements. | Missing/Incomplete | 0business_rnd_innovation
|
gen_af3ac7aba4dd0dc22110cf6200bd6169 | Cybersecurity Toolkit for HealthTech | Innovate UK | Lambda Functions Limited | HRCS22_21579 | This project will determine the feasibility of building a cybersecurity toolkit for manufacturers of medical devices and digital health products. The toolkit will give manufacturers a cost effective way to ensure cybersecurity in their products and meet their regulatory obligations. The toolkit will use a web based assessment to identify gaps and relevant cybersecurity actions, customising guidance for the specific product. Unlike penetration testing, the toolkit can be used early in the product development lifecycle, when it costs less time and money to remedy vulnerabilities. | Missing/Incomplete | 0business_rnd_innovation
|
gen_dc611a3d0f86ee0912aa0a4ddc2a2778 | Home Cervical Smear Test | Innovate UK | Lbn Innovations Ltd | HRCS22_21581 | 99.7% of cervical cancer is caused by Human Papillomavirus (HPV). Pre-malignant changes to the uterine cervix can take approximately 10 years following HPV infection to develop. This means that if the pre-cancerous mutations are caught early, then cervical cancer may be prevented. In 1988, the NHS Cervical Screening Programme was established and is estimated to have saved up to 5000 lives a year since its inception. Despite its proven track record, approximately 1 in 4 women in the UK fail to be screened. 2 women a day die, on average, with approximately 850 deaths a year. The greater percentage of these deaths according to Cancer Research UK is from non-white minority ethnic groups. The World Health Organization estimated in 2018 that 570000 women worldwide were diagnosed with cervical cancer, with approximately 311000 dying unnecessarily from this disease. Research outlines the barriers women face undergoing a cervical smear test. These include embarrassment, fear of pain and anxiety. Factors that can contribute towards pain are small anatomical size, a retroverted uterus, vaginismus, nulliparous, menopause (vaginal atrophy), female genital mutilation (FGM) and prior sexual assault. "I have experienced pain when having a pap smear done. The reason I had such terrible pain was the wrong speculum size (the one that was used was for a woman who had had several children). I've never had children. I was shamed and embarrassed by the experience...It was almost like I was to blame for the pain and discomfort." Despite these barriers being identified, the methodology for performing this test has not changed for the last 143 years; not since 1878, when Thomas Graves revised Edward Gabriel Cusco's speculum to include two curved metal blades. "My doctor dismissed my pain and having been through sexual assault, pap smears were never just uncomfortable, they were mentally traumatic." LBN Innovations Ltd is listening to women and developing a new, compact medical device to replace the speculum. By developing a new smear test methodology, we hope to encourage more participation in screening programmes and so save lives. | Missing/Incomplete | 0business_rnd_innovation
|
gen_d5ef55c51403706b8a088a88f7bcd9f1 | Luminate On Demand | Innovate UK | Luminate Consultancy Limited | HRCS22_21593 | Luminate Consultancy Limited is a leading London-based mental wellbeing consultancy working with organisations across the UK, supporting the health and wellbeing of their employees through strategic consultancy, training, counselling and other wellbeing sessions & activities. The business is launching Luminate On Demand, an application designed for mobile (also optimised for desktop) that enables employees in organisations across the UK to access relevant science-backed education, content, exercises and activities to support their mental wellbeing. Each organisation will have a tailored version of the application to support their current wellbeing programme and provide an integrated employee solution for managing mental health and wellbeing at their company. The project will ensure that every employee has access to content and exercises that will help them improve their mental wellbeing, drawing on a range of disciplines from mindfulness, cognitive behavioural therapy, behavioural science and modern psychology. We are taking employee wellbeing to the next level, tying together our consultancy work, our live offering and our in-person services with a technology product that supports this learning and provides a solution that can reach employees in any location, at any time, evolving with the world of modern working. | Missing/Incomplete | 0business_rnd_innovation
|
gen_b2a37444284259a65841230101df0129 | An innovative automated eye drop dispenser aid for the self-administration of eye drops to increase independence in the ageing population, improve eye health outcomes and reduce NHS/social care costs | Innovate UK | Medcam Healthcare Limited | HRCS22_21608 | Eye medication is unique as it is usually self-administered as eye drops. Eye drop application, however, presents a major challenge, particularly for older patients. Studies show that over 50% of patients actually miss their eye and 20% of people cannot apply sufficient force to squeeze the bottle, requiring someone else to apply the drops for them. Due to the variety of bottle designs and treatment regimes, so far no solution has been found other than district nurse input, or occasionally hospital admission. For those who can afford it, private carers are occasionally employed. Without social care input, many of these patients would miss vital medication, which could result in progressive sight loss and the associated health and economic burden. Sight loss has a severe negative impact on a person's life, affecting their work, social life, physical and mental health. Improper drop application presents a huge cost to the NHS and social care budgets. When this is combined with associated sub-optimal clinical care, including increased hospital visits and escalation of treatment, as well as visual impairment, the cost is far higher. The long-term demographic trend of an ageing UK population means that over the next 20 years, a 50% increase in cataract surgery and 44% rise in glaucoma cases are forecasted and many more patients will be requiring district nurse input. To meet this challenge, we have developed a novel device to aid the self-administration of eye drops. We have designed the world's first fully automated eye drop dispenser. This handheld device will enable even the frailest of patients to safely and accurately self-administer their own eye drops. Our device will be the first of its kind and has been designed to overcome the major challenges associated with the self-administration of eye drops. Research has shown barriers to self-administration to be both physical and cognitive and our device is the first to address every issue that these patients have. This device will reduce the risk of sight loss, allowing elderly patients to continue to live fulfilled independent lives, contribute to society, and take control of their own eye health without relying on others. Making drop application more accessible to all helps to reduce inequalities in eye health between those that have the ability to apply their own medication or pay for private carers, and those that cannot. | Missing/Incomplete | 0business_rnd_innovation
|
gen_364050200562b5875bafbbaedb5954d2 | Reducing the mortality rates for diabetic foot ulcers using AI in predictive healthcare models | Innovate UK | Medical Intelligence Group Ltd | HRCS22_21609 | no public description | Missing/Incomplete | 0business_rnd_innovation
|
gen_20ac58936276c732c9bfebd1f7f8a9c2 | Medicine Discovery Catapult Core Delivery Programme | Innovate UK | Medicines Discovery Catapult | HRCS22_21613 | Awaiting Public Project Summary | Infrastructure | 7research_infrastructure
|
gen_9ffa039131d68a566654ae5564d8294d | RespiTrain - A novel medical technology to reduce mechanical ventilation duration by 30% | Innovate UK | University of Oxford | HRCS22_21632 | no public description | Missing/Incomplete | 6project_grants_public
|
gen_43ce81d024684824728370d3a8484831 | Collecting the data for, and developing a predictive model to identify lapse and relapse to support people who want to change their relationship with alcohol | Innovate UK | Mind Health Ai Limited | HRCS22_21639 | Mind Health AI is a digital therapeutics start up, making cutting-edge science and technology accessible to both consumers and clinicians. We support individuals who want to change harmful behaviours and self--manage chronic health conditions, via predictive models generated by machine learning. We have a diverse, UK-based founding team with expertise in clinical, commercial and technical domains. Our combined professional experience provides a wealth of relationships, with realistic routes to market and institutional investment, and real potential for scaling. Our first product is alma, a mobile application which helps users beat cravings and quit drinking. Alcohol consumption is linked as a causal factor to more than 60 diseases, but although a range of interventions has been available for decades, the parlous state of care for alcohol dependency means that 90% of people who go through rehab relapse within five years. On this specific project, we seek to recruit users, building a dataset large enough to inform algorithms that can predict negative health outcomes, including cravings, lapse, full relapse and service disengagement. We are working with academics at the global forefront of their fields in behavioural science, predictive models and digital therapeutics. The value proposition of our product has been validated by stakeholder groups, including people seeking to quit drinking, as well as clinicians and professionals in related industries such as insurance and pharmaceuticals. | Missing/Incomplete | 0business_rnd_innovation
|
gen_91a0dc23ebc2b693b5501f83e3bb3e40 | Skindar: Skin disease prevention using LiDAR | Innovate UK | Missioncontrol Technologies Ltd | HRCS22_21644 | Melanoma skin cancer is the 5th most common cancer in the UK, responsible for thousands of deaths per year, however a high majority of cases are curable if they are diagnosed and treated early enough. Using various new technical innovations, we aim to reduce skin cancer incident rates with self-driven early detection and prevention, via an accessible, intuitive and consumer focused solution. We highlight the key points of difference of our technical innovations against the current state-of-the-art, as well as providing detailed information on the problems we are solving in our specific area of innovation. Our project offers various benefits, including economic and societal, which have the potential for widescale positive impact. | Missing/Incomplete | 0business_rnd_innovation
|
gen_dfab52d6c6cf876d5a903185cee8bfe1 | Simplifying and commercialising a portion controlled container and app to assist people looking to attempting to limit snack or alcohol intake | Innovate UK | Modereat Ltd | HRCS22_21646 | Modereat (Modereat) is a UK-based health and fitness SME lead by Christine MacCuish. Modereat is solving a significant unmet need with its controlled-release container designed to help those trying to regulate their snack intake or alcohol intake. Modereat links to a user's smartwatch fitness apps or smartphone step counter, releasing a snack from a preloaded and locked container when a set exercise threshold or time is reached. Modereat only provides users with one snack or drink rather than access to the entire contents of the container to reduce overconsumption. | Missing/Incomplete | 0business_rnd_innovation
|
gen_f0d8d1f220513d912d8c58efff939871 | Accelerating the commercialisation of BREATHE (MOF-Based unit foR genErATing Hospital-gradE oxygen) | Innovate UK | Mof Technologies Limited | HRCS22_21648 | The expanding pervasiveness of chronic obstructive pulmonary disease (COPD) and other lung disorders due to rising environmental pollution and changing lifestyles (smoking), the rising geriatric population which is prone to various respiratory disorders and the COVID-19 outbreak have resulted in an unforeseeable global demand for oxygen. To meet this increased demand and ensure hospitals and doctors have enough on-demand oxygen capacity to treat all patients, MOF Technologies have developed a unique MOF-based technology that boosts energy-efficiency and oxygen purity outputs in the oxygen concentrator market. MOF Technologies is the world-leading company in the manufacture and commercialisation of metal-organic frameworks (MOFs). MOF Technologies has a unique team of MOF experts and state-of-the-art facilities for the production and testing these material under real gas conditions. MOFs hold the potential to positively impact the lives of everyone, everywhere due to their unrivalled affinity to capture, store, and release gases. Through BREATHE, we are looking to unlock the power of MOFs for the benefit of people around the world, at a time when oxygen generation has never been more crucial. This project will accelerate the commercialisation of this new MOF-based technology through novel marketing and business development strategies by implementing innovative value co-creation approaches with international partners. | Missing/Incomplete | 0business_rnd_innovation
|
gen_9c3966e9e29bf02f96cdaaa14d8e8c87 | Development of rapid semi-quantitative point of care (POC) device for ammonia detection | Innovate UK | Molecular Quest Healthcare Ltd | HRCS22_21649 | Ammonia detection in whole blood has applications in the diagnosis and management of many hepatic diseases, including cirrhosis and rare urea cycle disorders. Current techniques for ammonia measurement suffer from limited range, poor resolution, false positives or large, complex sensor set-ups. The current project is undertaken to develop a method and a disposable single-use point of care device for ammonia testing in blood including all chemical reagents. The aim is to develop a technique utilizing inexpensive reagents and simple methods for detecting ammonia in minimum volume of whole blood. Since, we aim this kit to be used at the source with minimum laboratory procedures and no sample processing steps. Hence, the present study will aim to develop methods to separate or withhold red blood cells or impurities in the blood sample that could adversely affect the measurement of ammonia. The sensor would exploit the modified form of the indophenol reaction, which resists sources of destructive interference in blood, in conjunction with a filter membrane. The product will have a sensing scheme that is selective against other amine containing molecules such as amino acids and has a shelf life of at least 50 days. Additionally, the resulting system will be modified to have high sensitivity and allows for the accurate reliable semi-quantification of ammonia in whole human blood samples at a minimum range of 25 to 500 µM, which is clinically relevant for rare hyperammonemic disorders and liver disease. | Missing/Incomplete | 0business_rnd_innovation
|
gen_e6f4e1b7b31f042664b363de83aaa60c | Glisten: The Power of Song | Innovate UK | Musikind Ltd | HRCS22_21663 | Glisten is a mobile App that utilises the benefits of music to help counteract the challenges of isolation and cognitive and physical decline in older adults and those living with dementia. The App has been designed by a Music Therapist specifically for older adults who are being cared for in a home setting. The App's key feature is an online studio that enables carers to assist the older adult/s they are caring for to record and share their songs with loved ones. Glisten also includes musical activities to encourage physical movement and cognitive engagement. | Missing/Incomplete | 0business_rnd_innovation
|
gen_eabfdebdb4c4a35241a7816080f98117 | Demonstrating proof of concept for inclusive antenatal education | Innovate UK | Muther Tongue Group Ltd | HRCS22_21664 | It is well proven that the physical changes a woman experiences after having children can have a significant impact on her mental health, whether it's the baby blues, postnatal depression or PTSD following a traumatic birth. Poor maternal mental health outcomes are not only costly to women and their families but the wider society. Where this intersects with poor health literacy the impact can be even more devastating and isolating. Now, imagine a service that is responsive to every stage of your birthing journey, allaying fears you didn't even know you had -- all at the touch of a button in your native language. Would that put your mind at ease? Muther Tongue is an evidence-based online multilingual education programme for mums to gain confidence and control around their transition to parenthood, before and after childbirth. Our goal is to make birth preparation education more inclusive, personalised and safer for all women, thereby reducing any stress and anxiety. Designed to fit around the modern woman's life, users are able to stream bitesize videos anywhere from any device -- delivered by experienced NHS practitioners in a woman's mother tongue. | Missing/Incomplete | 0business_rnd_innovation
|
gen_8fb124b3b2b07bb259482ca8f13e4e72 | Design and Pilot Study Testing of "The MyGo" - a functional, wearable, electrical stimulation garment. | Innovate UK | Mygo4ward Ltd | HRCS22_21668 | Mygo4ward Ltd are developing "The MyGo" - an affordable, innovative and wearable technological garment, to improve the mobility and the lives of People with spinal cord injury and neurological disorders. There are 30 million people in UK, Europe and North America living with these disorders and, the company estimates, The MyGo would improve the health, wellbeing and quality of life of up to 80% of these people. Spinal cord injuries and neurological disorders often render people unable to access normal movement and basic functional activities such as standing and walking and "The MyGo" is specifically to improve the quality of life and opportunities, for these people. This project will investigate design options on the garment, the control unit and its general functionality, helping the company proceed towards full clinical trials and entering the global marketplace. | Missing/Incomplete | 0business_rnd_innovation
|
gen_774785e6671956a7cd79ae0876b8fe13 | AI Musical Instrument/Therapies as a Self-Driven Healthcare Solution to Support Mental Health | Innovate UK | Nada Brahma Ltd | HRCS22_21673 | Musical Nutrition is about giving you the most powerful 'Musical Nutrients' to support your mental health. Our Musical Nutrients incorporate not only your preferences for where you want support but also your bio-feedback from your heart rate and brain waves. We're introducing a new process of bio-resonant audio that can personalise music and wellbeing activities to your bio-rhythms. Furthermore, instead of just playlists, we're bringing you the best of evidence based music therapy activities that can give you key resources for making measurable neurological and cognitive improvements that can translate into real life outcomes. This is a Self-Driven Healthcare solution. Enabling you to take control over your mental health and wellbeing with the best of evidence backed methods and a state of the art bio-resonant audio technology. | Missing/Incomplete | 0business_rnd_innovation
|
gen_b4d9dd5b0440689f6fae7c69ef067a25 | A new pelvic membrane from graphene and stem cells technology | Innovate UK | Nanoregmed Ltd | HRCS22_21679 | no public description | Missing/Incomplete | 0business_rnd_innovation
|
gen_40eedd2c9d34944ce621d5ca9e75689b | SWIM - Self-management Wearable for Improved Mental wellbeing | Innovate UK | Neurobright Ltd | HRCS22_21685 | Mental health is a bigger problem than Cancer, Diabetes, and Chronic respiratory disease combined, affecting more than 1 billion people worldwide and costing the global economy £1 trillion each year. In the UK, one in four people will have a mental health issue with 79% feeling stressed or anxious about work, resulting in 70 million workdays lost each year and costing the UK economy £118 billion. NeuroBright is developing the world's first smart, wearable device that uses brain sensor technology (EEG) connected with AI to deliver light and sound programs that reduce anxiety and stress. It's head-worn with LED eyewear in front of the eyes, and using earbuds to synchronise light and sound frequencies with the brain - like being entranced by a flickering flame while listening to calming music to soothe the mind. EEG will provide brainwave data to deliver personalised user-programs that perfectly guide their mind into a desired neurological state ie. relaxation. The project is based on 50 years of scientific studies that show how effective light and sound is for improving mental wellness in a non-invasive, safe way, with no side-effects. NeuroBright's device is app operated and easy to use, helping manage mental wellness without the need for pills, long NHS waiting times, or paying for expensive therapy. NeuroBright's philosophy is to create a product that's widely available and affordable, that delivers fast results with long-term gains and no need to learn or do anything other than sit back and enjoy the experience. NeuroBright will also connect with your digital assistant, so you could simply ask 'Alexa', or 'Siri' for a relaxation session to help you switch off and enjoy your evening. NeuroBright has been in development for over 3 years with the project focus now to take the hardware and app to a commercialised stage. The project will involve setting up workplace trials with global organisations, with the intention of giving their workforce a device they can easily and safely use to help them reduce their stress, anxiety, and manage their mental wellness. This is particularly important in the wake of COVID-19 and the impact it still has on mental health, and the need for a solution for the home-office working model adopted by many businesses. NeuroBright will work with a world-class design partner on this project to ensure our device looks amazing as well as creating a world of healthier minds and happier people! | Missing/Incomplete | 0business_rnd_innovation
|
gen_8e1471cdb57c6e4511b61e024d6639b5 | Feasibility of Asian and Middle Eastern markets for the suitability of Nexa's Negative Pressure Wound Therapy | Innovate UK | Nexa Medical Limited | HRCS22_21693 | Nexa Medical Limited plans to undertake a feasibility study into the export of its medical device, Nexa Negative Pressure Wound Therapy, to specific countries in the Asian and Middle Eastern territories. As a UK based company, the commercialisation focus has been on the UK market. With the success of a recent UK distribution agreement, Nexa wants to export its products to other markets that are of commercial interest. The Asian and Middle East markets have exceptional growth of negative pressure wound therapy, but it requires specialist help and knowledge to access these markets. The feasibility study will aim to answer regulatory, distribution and commercial questions about exporting and selling into these markets. The countries of focus are Singapore, Malaysia, Thailand, Saudi Arabia, Kuwait and the United Arab Emirates. Nexa Medical has a planned product pipeline based on the core patented technology but market specific information is required to feed into the technical and user requirements in order to ensure the customer needs are fully met. A key goal of this feasibility project is to collect this information in a formal way by engaging with healthcare and sales professionals in the different markets. | Missing/Incomplete | 0business_rnd_innovation
|
gen_a3d27554efd183d75b5066a56ac29777 | Novel small molecule enhanced NK cell immunotherapy | Innovate UK | Nk.Io Limited | HRCS22_21696 | Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details. | Missing/Incomplete | 0business_rnd_innovation
|
gen_de7a5b160c022406b2ae874be21eb2c0 | UK-Canada AgeTech Innovation Exchange | Innovate UK | Northern Health Science Alliance Limited | HRCS22_21701 | no public description | Missing/Incomplete | 3networking_collaborative
|
gen_8095e1d8954060960a5257253398f55f | Building international partnerships for stroke rehabilitation | Innovate UK | Nudge Reality Limited | HRCS22_21711 | 15m strokes occur each year worldwide, including 100,000 in the UK, 795,000 in the USA and 1.1m in Europe. 2/3rds of patients are left with some form of cognitive impairment and in the UK the societal cost of stroke is £25.6 billion/year and forecast to treble between 2015-2035 as the ageing population grows. Conventional care involves repetitive tasks to relearn cognitive function, which is hard, tedious work with little feedback on progress. NICE recommends 45 minutes of inpatient therapy, five days/week but this is seldom fulfilled due to staffing shortages and cost pressure. Virtue is the first immersive Virtual Reality (VR) programme developed for the rehabilitation of cognitive function after a stroke, stimulating new areas of the brain to compensate for damaged ones. It mirrors the approach used by Occupational Therapists, helping patients re-learn the activities needed for everyday living, such as getting dressed, preparing food and going shopping. A 40-inpatient clinical trial of the prototype has shown that stroke patients engage with it, recover more strongly and can be discharged earlier. Yet the UK represents less than 1% of the global market for stroke care and while it remains key, adoption within the NHS is a slow process. To maximise our chances of commercial success we need to develop partnerships to reach other, readily accessible markets with similar healthcare demands in parallel. To that end we will focus on entering the US and European markets, both having established and well regulated healthcare systems, and the Middle East, where many countries are early adopters of technology with favourable reimbursement pathways. The main outcome from this study will be the establishment of early overseas partnerships that provide access to new markets and open up new opportunities for commercialisation. The deliverables from the project will be three strategic marketing plans for each territory which will detail the business model and execution plan. | Missing/Incomplete | 0business_rnd_innovation
|
gen_53c1545793e8721e1bcf499ae0dce170 | Developing E-Plasters to enable self-management of rapid and complete wound healing | Innovate UK | Nutissu Ltd | HRCS22_21714 | Efficacious wound healing is a huge unmet clinical need. Wounds pose a significant economic cost to the healthcare system, and the society, but the impact often under-recognised. International Diabetes Federation shows, more than 460 million people are living with diabetes worldwide and by 2045 this number is expected to rise to 700 million. Diabetic foot ulcers usually turn out to be infectious and at times patient may end up with amputations. Yet, wounds can often lack priority, and investment. Wounds are not considered a disease, and chronic wound patients are assigned to long term wound management, and just "live with it" as therapies exist that slow down the advancement of wounds, but rarely reverse completely the problem. Thus there is a real need to address this. We aim to enable a better quality of life and facilitate significant cost savings to the NHS through our innovations based on biomaterials and biolectricity. This project will enable us to develop E-plaster(r), to enable self-management of chronic wounds using personalised, intuitive, patient centric therapy to rapidly and completely heal chronic wounds, and to ensure that acute wounds heal rapidly without acquiring complications. | Missing/Incomplete | 0business_rnd_innovation
|
gen_dd2008f729a3466b76f1f7396422209d | Towards massive scale-up of low-cost growth factor production for meat cultivation | Innovate UK | Occam Biosciences Limited | HRCS22_21719 | Industrial livestock farming methods are associated with undesirable environmental impacts including greenhouse gas emissions, high water/land usage, and animal welfare/ public health concerns such as overuse of antibiotics and zoonoses. The worldwide population is expected to reach 8 billion by 15/11/2022, and 10 billion by 2050\. Finite resources and increasing worldwide meat consumption create conditions for global food insecurity. Cost-effective, disruptive innovations in production technology for nutritional proteins are therefore required for the industrialization of meat alternatives. Such a shift to **cultivated meat** (**CM**) production will disrupt this highly valuable global industry ($467 billion for beef in 2021). CM is meat grown from animal stem cells in a bioreactor using tissue engineering approaches. Stem cells are differentiated into cell types found in meat such as muscle and fat in specialized nutrient-enriched cell culture medium containing **growth factor** (**GF**) proteins. These cells are combined with scaffolds to form meat products. Thus, CM is produced in a controlled environment without farming animals for food, mitigating many of the concerns associated with conventional farming. **However, economic feasibility and scale-up are major barriers to the adoption and public acceptance of CM.** **Key cost drivers** are the **GF components** of culture media. Existing GF protein production and separation methods (a critical purification step) are prohibitively expensive to transition from laboratory to commercial production scale. _Indeed, modelling studies show current CM production costs between $50,000-400,000USD per kg using the growth factor FGF-2, at a cost of $5,000/mg in a 20,000L bioreactor. Only by reducing FGF-2 to nominal costs can we approach commodity level prices of $2 per kg._ **Our vision is to target this bottleneck enabling massive scale-up of low-cost growth factor production for meat cultivation**. To generate low-cost GFs, we will deploy our plant-based GF bulk-expression platform, and combine with novel low-cost alternatives for bioseparation/purification. This is achieved using an inexpensive approach exploiting sustainable commercially-available industrial food-grade substrates. Pilot data has shown this is an effective method for purifying crude protein extracts with high recovery of biological activity. Significant cost reductions for GF production are envisaged, with profound commercial, economic, sustainability and environmental impacts. | Missing/Incomplete | 0business_rnd_innovation
|
gen_bd0005366ff983aa47d37a89d88ead28 | OGI Bio Follow on Fund - COVID Resilience Fund | Innovate UK | Ogi | HRCS22_21726 | In the microbiology sector, early stage R&D involves large amounts of manually culturing microbial samples. This is inefficient for companies, who would like to automate, but existing automation is expensive and tailored for mammalian cultures. Furthermore, the current method for estimating microbial growth doesn't provide sufficient information for industrial biotechnology applications, pharmacological work on antimicrobial resistance or academic research, because all these sectors require accurate information on cell morphology as well as cell number and biomass. OGI will offer customers an inexpensive route into routine microbial culturing on a system that is smaller than more expensive systems currently available but is also modular, allowing customers to retrofit additional functionality to our system as and when required. This includes novel and increased analytical information such as inline, automatic microscopy imaging of individual cells within the population. | Missing/Incomplete | 0business_rnd_innovation
|
gen_ab4a041a8313ebf42d227fe846d28df9 | Omm is an AI powered mobile phone application based on a proprietary algorithm which generates, tracks and optimises personalised guided audio-based therapies | Innovate UK | Omm App Limited | HRCS22_21729 | Mental wellbeing costs the global economy $1trillion/year (WorldEconomicForum). Current solutions have drawbacks: therapy is expensive (£40-100/session), prescription drugs have side-effects and generic wellbeing apps don't work for everyone. Omm are the developers of a new generation of personalised wellbeing apps that can help people self-manage mental wellbeing more effectively and at lower cost. Omm creates personalised, guided audio tracks that enable the user to build habits that work for them. An AI-powered personalised recommendation engine will then be used to improve the user experience with each session and deliver measurable results. The Omm vision is to deploy this tech starting with meditation (worth £6bn globally, in scope for this project) and expanding to verticals such as fitness, recovery, yoga, CBT and therapy. This approach is different because current applications are not personalised to the user and are inefficient given content production time and overlap. For example, in the meditation market, existing apps are generic content libraries providing on-size-fits-all content that often fails to deliver results. Omm uses AI and fuses multiple data sources to provide interventions tailored to the individual. | Missing/Incomplete | 0business_rnd_innovation
|
gen_239025e77bd323006030ff0ad16427a8 | Levata | Innovate UK | Orchard HouSE Designs Ltd | HRCS22_21739 | Levata is an adjustable, user centred footrest for patients with lower leg Oedema that has been developed with clinical staff at Royal Brompton hospital to be used both in hospitals, care homes and most importantly in outpatient's homes. Levata began by a request from Hospital staff in Royal Brompton and Harefield Hospital for an improved design for footrests used with patients with Lower Leg Oedema. Oedema is a condition where limbs become swollen as a result of excess fluid in the body, commonly caused as a side effect of cancer treatment, heart disease, surgery and childbirth. Multiple clinical articles detail the under-treatment of Oedema and the drastic impact on quality of life for patients along with poor treatment pathways. I proposed an array of different solutions and produced a full size looks-like prototype for the end of year show in central London where I won the award for "Most Manufacturable" project in show. After graduating I applied to, and won, the Young Innovators award to help establish my business. I have been working on the project full time and intend to deliver the first batch of Levata footrests by the start of 2023\. | Missing/Incomplete | 0business_rnd_innovation
|
gen_904cd2a9046a81cfee86c8974be141f7 | BEACON (BEd bAnd proof of CONcept ) | Innovate UK | Person Centred Solutions Ltd | HRCS22_21774 | High quality sleep is essential and has a major impact on health and wellbeing. Globally, over 1.7 billion people have musculoskeletal conditions such as multiple sclerosis, arthritis, and muscular dystrophy and over 77 million have survived a stroke. It is common for people with the conditions listed to have mobility limitations that can prevent them from achieving high-quality sleep each night, resulting in direct and indirect healthcare costs. Lack of good quality and quantity of sleep can lead to further health issues, such as cognition problems, high blood pressure, cardiovascular disease and increased incidence of anxiety and depression_._ The market for sleep aids globally is £49.62 billion in 2020, this figure is predicted to rise to £92.82 billion by 2030\. With mattresses and pillows being the most lucrative form of sleep aid on the market. BEACON will evidence and enable the Bed Band, a patent-pending health and wellbeing device developed using advanced manufacturing and materials by Person Centred Solutions that improves sleep quality for people who struggle to maintain a comfortable position in bed. The device helps users reduce their incidence of insomnia, pain, and discomfort resulting in improved sleep and lower costs of care. The UK addressable market for people with mobility limitations alone for the Bed Band exceeds 11 million people. The BEACON project will evaluate the Bed Band in people with mobility issues who struggle to get a good night's sleep due to discomfort -We will measure the amount and quality of sleep using validated sleep monitoring technology and user surveys -Results will support commercialisation by 2023 | Missing/Incomplete | 0business_rnd_innovation
|
gen_e1a04f973d207ce7278c1d2663e458f2 | International Feasibility Study with Sri Lanka for Innovative Manufacture Facility of Retinol as a Pharmaceutical Grade API. | Innovate UK | Phytoceutical Limited | HRCS22_21786 | Phytoceutical and Regenall have formed a partnership to exploit their IP (Patent and Patent applications) and clinical trial applications (CTA) in the health and medical sectors. Core to both companies IP and CTAs is vitamin A including the form retinol (where molecular size allows skin penetration) used in skin and tissue regenerative medicine. However, retinol is reactive and unstable but Phytoceutical have, including studies with the University of Surrey and NPL, demonstrated their nano-micellar delivery platform successfully stabilises and delivers retinol into skin and tissue. Retinol is supplied by a small number of reputable global suppliers however nano technology requires a high purity grade only available from laboratory suppliers at high prices or at lower cost and quality. There is no Pharma grade readily available at a cost effective price in the form required as an active pharmaceutical ingredient (API). Conversations have taken place with the Sri Lankan High Commission with offers to support a compact modern Pharmaceutical manufacturing plant, initially for retinol API synthesis, in a Sri Lanka Free Trade Zone. This project main focus is to build international research and innovation partnerships and networks for the technical, regulatory and commercial feasibility to set up such a facility. Key objectives include researching freedom to operate i.e. existing IP/patents to guide inventive synthesis approach. Technical: Research the feasibility with local Universities of novel retinol synthesis from local produce for a new Pharma grade. Regulatory: Research and conduct due diligence with the Sri Lanka medical regulator NMRA and UK regulator MHRA for facility Pharma GMP approval in Sri Lanka for API to be used in UK Pharma product manufacture for UK and EU markets with future steps to manufacture these for local and Asian markets in Sri Lanka Commercial: Due diligence to be conducted and meeting with potential local interested parties including State Pharmaceutical Corporation and Board of Investment. Sri Lanka needs new high tech industries and support is willing but requires interaction on the ground. High-tech compact facility for synthesising retinol as an API for UK manufacture and export is innovative, extending facility in future to produce nano-micellar IP protected products to Pharma GMP for Sri Lankan and Asian markets brings innovative manufacturing to the local country supporting hi value jobs and exports. Benefits accrue back to the UK supporting product manufacture in UK for global EU and USA markets, creating jobs and tax revenue in the UK. | Missing/Incomplete | 0business_rnd_innovation
|
gen_2c09b91f998c956a6e00fc85eed66e3a | Lungy + BreathUI: An immersive breathing platform | Innovate UK | Pi-a Creative Systems Ltd | HRCS22_21788 | The coronavirus pandemic has placed new emphasis on the importance of breathing and breathing health. Pi-A have developed a new technology, BreathUI, that recognises user breathing. 'Lungy' is a smartphone application, developed by Pi-A, that uses BreathUI technology to encourage regular breathing exercise in the management of both respiratory disease and for relieving symptoms of mild anxiety, stress, depression, and insomnia. The application will encourage and guide users through a range of relaxing breathing exercises, promoting not only breathing function but also focus, user engagement, and mindfulness. The application would enable tracking of user progress, enabling the creation of user-profiles and progression via personalised breathing profiles for every user, supporting and replicating the role of an attentive therapist. The application is intended to be accessible and engaging for everyone, but also to improve both physical and mental health, through regular breathing exercise. The Audience of the Future Grant will be used for research, testing and prototyping on the interaction between the user and BreathUI technology. It will be used to inform the development of Lungy to ensure the application is engaging to a wide audience. It will also be used to explore other potential applications of BreathUI technology, which may have uses in healthcare, as well as other sectors, as an immersive user experience. | Missing/Incomplete | 0business_rnd_innovation
|
gen_5ed444c5ee3722a855e7219b149550c3 | Live Life without Diabetes | Innovate UK | Pink Green Health Limited | HRCS22_21791 | **Vision** * The ultimate vision is to see a world without lifestyle-related, preventable type 2 diabetes, and its associated complications and often devastating impact on people's lives, friends and families. This includes the physical and psychological cost of the disease, and long-term financial costs to individuals, societies and nations. While this is the vision our objectives remain rooted in reality in the short and medium term. **Key Objectives** * The Live Life without Diabetes project has a clear aim to achieve Diabetes remission (i.e. not diabetic) for those who are on the program. Based on other similar projects we estimate an ability for 50% of those who enter the program to achieve complete diabetes and pre-diabetes remission (normal Hba1c blood levels at year 1 which is the blood test to check for diabetes levels) with sustained remission and reversal and long-term education and knowledge base growth from patients in their future management. **Main areas of focus** * The project director is currently working with Primrose Hill Surgery in North Central London CCG with an aim to achieve Diabetes remission in up to 50% of the patients in the surgery. The aim for 200 patients to achieve diabetes remission, or to reach non-diabetic status if they were pre-diabetic. (In total there are 427 patients -- 6% of the GP practice population with pre-diabetes or type 2 diabetes). * To achieve repeatability and scalability of the program, grant funding is being requested to part digitalise the program so it is accessible to a wider and future audience who will invariably need this support to improve their health outcomes. * The program will currently be run as group workshops with high intensity over 12 weeks and close follow up of physical health outcomes, but we require digitalisation of the product so the intended successes can be measured and repeated on a larger scale and the ability to compete for contracts within the NHS (e.g. Diabetes Prevention Program and programs for type 2 diabetes remission) * Funding would also increase staffing available for development and delivery; allow more patients to access the product in the first 12 months initially GP across practices in Camden and create a clear business case alongside clinical expertise with an aim to create a product that is able to deliver at scale across the NHS, private sectors and worldwide. | Missing/Incomplete | 0business_rnd_innovation
|
gen_ddef384479bb56d14325fde96c5a0719 | The Best Outcomes for Breast Cancer Patients | Innovate UK | Pomegranate Technology Ltd | HRCS22_21798 | The most accurate way to decide treatment for breast cancer patients, improving their chance of survival, is brought to market by this project. Calculations for deciding treatment are currently based on averages, meaning it is not as targeted to the patient as it could be and healthcare inequalities are deepened. Algorithms are applied in a ground-breaking way by this user-friendly and informative website to take into account data applying to each patient individually. Thus the outcomes can be improved. | Missing/Incomplete | 0business_rnd_innovation
|
gen_c8e71a8bbcb4517f20dc91ca552320dc | Proton Health: a full-stack digital health app designed to tackle eczema. | Innovate UK | Proton Health Ltd | HRCS22_21806 | Proton Health is a digital app tackling eczema, a skin condition affecting over 550M patients globally. We use cutting-edge science, personalised coaching and behavioural therapy to control symptoms. Delivered as an individualised programme, we combine bespoke insights, educational sessions and a personal Skin Coach to enable effective self-management and the prevention of disease flare-ups. | Missing/Incomplete | 0business_rnd_innovation
|
gen_31ecd59204a240966ed7e2b1d55d1259 | QV Bioelectronics USA cooperation feasibility study | Innovate UK | Qv Bioelectronics Ltd | HRCS22_21821 | Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and patient life expectancy is just 14-months post-diagnosis on average. Electric field therapy is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slowing tumour recurrence and prolonging life. However, the single marketed device for glioblastoma is not recommended for use on the NHS by NICE due to poor patient quality-of-life and low cost-effectiveness. QV Bioelectronics (QVB) are developing GRACE, a novel implant that delivers electric field therapy in a focal and continuous manner, potentially doubling glioblastoma patient life expectancy, leading to potential improved patient outcomes whilst overcoming quality-of-life issues associated with existing solutions. QVB is seeking to access partners in the US who have specialist knowledge, technologies and capital available to bring the GRACE device to market. QVB's device is still undergoing pre-clinical development and will not be ready to be prescribed to patients for several years. QVB's technology will be expanded to other types of brain tumours in future, creating a combined global market opportunity worth over £5Bn/year, whilst providing a new treatment for NHS patients. This will generate UK jobs and help to cement the UK's position as global leaders in the growing field of bioelectronics. | Missing/Incomplete | 0business_rnd_innovation
|
gen_8d2f05376fcdbca0cf391482a40dc7e4 | Rawora Project | Innovate UK | Raw Revolt Limited | HRCS22_21824 | Recent covid levels have highlighted our still voidable state as a society, we all remember the physical isolation and the mental stress this imposes indiscriminately. Many of us found new creative hobbies to help cope, whilst platforms like Zoom played an incredibly important part in helping us feel connected, present, and less isolated from others. Covid has given us a better understanding of the importance of maintaining a healthy mental state, especially for those who have previously been struggling with mental or physical issues. Our team has taken its knowledge of remote off-site working from the creative industries and developed a creative community hub (RawOra) to enable creativity/interaction/communication/distribution. With successful funding, we will develop a working demonstrator/prototype, to launch into the marketplace for Beta-testing to source investment. As part of the project, we will work with Cerebral-Palsy poet Shaun Fallows[][0]as a demonstrator of how the hub can be used in practice. [0]: mailto:[email protected] | Missing/Incomplete | 0business_rnd_innovation
|
gen_72a478907a1083cc076e03550fb2dbef | Development of a modular postural support system (backrests) for disabled clients in wheelchairs and other mobility equipment | Innovate UK | Rehabco Limited | HRCS22_21830 | The world's population is both ageing and gaining weight and the period of time that people live with morbidity is increasing. With increased age comes reduced mobility which can have significant impact on health and well-being. Improving health technologies are also allowing people with disabilities (both acquired or genetic) to live longer and generating increased chances and opportunities for a productive life. Maintaining a sitting posture requires energy and if the person is not supported fully, they will expand additional energy in trying to remain stable. Asymmetry in any part of their body will add to their instability and therefore their energy output. Improving the contact between the sitter and their support surfaces will aid their stability, so making them less tired, reducing discomfort and increasing the time they are able to spend in the equipment. All of these 'physical' benefits translate into better emotional well-being. They are able to focus on completing tasks (rather than maintaining balance) and looking outward rather than inward. Focusing on optimising the fit of the backrest system to the wheelchair user will ensure that it meets their personal wants as well as their clinical needs: a, Discrete - minimal material will ensure the system is not bulky and be minimally visually intrusive. b, Clinically Efficacious - built-in adjustment will ensure good fit to the body allowing postural control to accommodate or correct the muscular-skeletal forces of the user. c, Continuing alterations - the ability to re-modify the contact areas as the client's posture alters with time, Most wheelchair backrest systems currently on the market consist of a single pre-formed metal shell with a foam insert to contact the user. In order to cover the various widths, heights and depths required by the population, a huge number of different shells have to be manufactured and held in stock. By developing a wheelchair backrest system that is modular, the same range that can assembled from a small number of critical components. Therefore, the up-front tooling costs are kept to a minimum, the held stock is significantly reduced and the supply time is improved. The ongoing costs to maintain a client's optimum posture will be reduced as the same backrest system can be adjusted and also 'improved' by swapping out individual components to meet a significant change - rather than replacing the complete system (as is the case in many backrests on the market today). | Missing/Incomplete | 0business_rnd_innovation
|
gen_e73eb3c31f3009a40a26f9e8eada99d9 | SehaMed Marketplace expansion | Innovate UK | Sehamed Global Ltd | HRCS22_21863 | SehaMed Global Ltd. are on a mission to make high-quality and innovative medical devices available to hospitals around the world. The company currently operates Europe's first and only MedTech marketplace which has been developed to connect innovative manufacturers with international distributors to drive the availability of innovation in healthcare systems globally. With key stakeholders such as manufacturers and distributors already integrated into their current SAAS application, their objective for this specific project is to integrate an additional pathway specifically for hospitals. This integration will allow hospitals around the world to access the marketplace, search for products and contact relevant local distributors (suppliers) all within one easy-to-use platform. The route to the international healthcare market i.e. from the manufacturer via the distributor to the end-user is highly fragmented. Manufactures need to find and appoint a suitable distributor and they in turn will need to promote those product(s) in all of the relevant healthcare facilities in their market. This lengthy process needs to be multiplied by 100+ countries for global reach and it is one of the main reasons for slow international expansion for manufactures and slow availability of innovation in hospitals. Our marketplace aims to connect the entire supply chain to drive growth for businesses and improve healthcare globally. Right now, the industry relies heavily on annual conferences, exhibitions and Google searches and with this expansion, the SehaMed Marketplace will become the first platform that supports the entire MedTech supply chain, with a truly global reach. | Missing/Incomplete | 0business_rnd_innovation
|
gen_3abbe54fc9c9ac44413f1cdac8f2c745 | Developing SENISCA's global network to meet future needs: grant applications, oligonucleotide synthesis, and pharmaceutical partners | Innovate UK | Senisca Ltd | HRCS22_21865 | SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cell aging. This innovation works by restoring the ability of cells to 'fine tune' the expression of their genes to rejuvenate aged cells. At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing. Because oligonucleotide therapeutics is one of the fastest-growing therapeutic sectors globally, cutting edge cell delivery technologies are in constant and fast-moving development. To stay abreast of these developments, SENISCA needs to dedicate a strong internal team to the task of securing world leading partnerships for oligonucleotide synthesis and cell delivery in-licensing. This will be a key success factor in our ability to reach Phase 1 to Phase 3 clinical-testing stage for our drug pipeline, and ensure that SENISCA becomes a leading Oligonucleotide therapeutics company globally. The success of these partnerships will also provide a solid foundation to bid for collaborative EU-based grant opportunities and open the door to future co-development pharmaceutical partnerships. We will be assigning research tasks to members of the SENISCA team, sub-contracting research to a drug development market specialist, and sourcing a pharmaceutical partnering agency to assist us with our partner search. We also aim to attend at least one networking event/conference in early 2022 (either online or in person) to increase our international network and visibility. This project will lead to innovation within the senescence field. SENISCA is proposing effective treatments (and potentially cures) for age-related diseases such as Idiopathic Pulmonary Fibrosis (IPF), Osteoarthritis (OA) and Age-related Macular Degeneration (AMD). These diseases currently have limited treatment and no cure. By starting the search for global partners, we will allow for the exchange of scientific knowledge and expertise, and we will accelerate SENISCA's R&D and route towards commercialisation. | Missing/Incomplete | 0business_rnd_innovation
|
gen_96064e94d043675c9cbb5f0bff9a06da | Investigating the feasibility of a new AI driven innovation that support self-management of mental wellbeing | Innovate UK | Sleepcogni Limited | HRCS22_21885 | Mental health includes our emotional, psychological, and social well-being. It affects how we think, feel, and act. It also helps determine how we handle stress, relate to others, and make healthy choices. However, with the impact of COVID, war in Ukraine and growing economic downturn there is a growing mental health crisis which the NHS was already unable to cope with, leading to an unsustainable backlog. Our unique ring trigger device delivers our patented treatment, Active-Biofeedback, personalised by the 12 physiological, behavioural and environmental sensors. The therapy uses light, sound and tactile cues personalised through a biofeedback system to help people relax, unwind and distract from their anxieties. One in four adults' experiences at least one diagnosable mental health problem in any given year. Mental health problems represent the largest single cause of disability in the UK. The cost to the economy is estimated at £105 billion a year -- roughly the cost of the entire NHS. Anxiety Disorder market size is projected to reach $13.03bn by 2027 and stress management market is expected to reach $20.6bn by 2024\. We require funding to conduct feasibility research into the user acceptance of the innovation to support self-management of mental wellbeing due to economic downturn, rising commodity costs and reduction in global investment. The current economic climate means that there is a high risk associated with this project which there is little appetite for at this time. However, there is an urgent global clinical need to support patient suffering from mental health issues. This grant funding will allow the business to accelerate development of the stress and anxiety product at a time when mental health issues are rising - due to the exact reason why public funding is needed. | Missing/Incomplete | 0business_rnd_innovation
|
gen_5abd569188790116624b91897266d984 | The Sleep Well Being Digital Project | Innovate UK | Snapdragon Psychological Services Ltd | HRCS22_21892 | The Sleep Well Being Digital Project is an online parenting resource to guide parents or carers to improve their children's sleep. The resource draws on the principles of Cognitive Behavioural Therapy for Insomnia (CBT-i) and takes a positive parenting approach. The Sleep Well Being Digital Project is aimed at parents or carers with a child between four and twelve years of age who is experiencing sleep-based anxiety, difficulty with bedtimes and/or waking during the night. The resource is comprised of short video tutorials and e-books which contain tools for parents to use with their children. There is access to an online forum for support and parents have the option to arrange one to one support at an additional cost. | Missing/Incomplete | 0business_rnd_innovation
|
gen_18b3e15d13421cd3f95b56d528b19be1 | Songbirds Music UK: Music Interaction Telepresence Robot Research Trial | Innovate UK | Songbirds Music UK Cic | HRCS22_21895 | Songbirds Music UK: Music Interaction Telepresence Robot Research Trial Songbirds Music UK (Northwest England) run an award-winning hospital musical interaction programme with children with complex healthcare needs and disabilities. SMUK will research, develop and evaluate the use of a telepresence robot as an interface for delivering enhanced remote live musical interaction sessions with hospitalised children in paediatric settings. The research will use music as a vehicle to innovate new knowledge for professionals across health and communication in using computerised devices to interact with patients at increased risk of isolation due to debilitating illness, limited communication, immuno-suppression and COVID-19 restrictions. | Missing/Incomplete | 6project_grants_public
|
gen_6e9526e5f577695bfc5b89dedb5b421f | Tarian Group Ltd proposal to seek funding and support for the accelerated development of an innovative solution that enables digital systems integration within healthcare, improving data flow between Primary, Secondary Care and patients. | Innovate UK | Tarian Group Limited | HRCS22_21920 | Tarian Group Ltd are group of working clinicians (GPs & a clinical pharmacist) and a technical architect working to develop an innovative solution that provides digital systems integration enabling data flow between digital healthcare systems and patients. The Tarian Group Limited team comprises 12 directors, 8 of which are GP partners, a clinical pharmacist, an IT architect and a senior accountant. The executive board currently contains 5 of those directors, who manage the direction and operations of the company. Our team has been working together for several years, and we have a cumulative experience in healthcare and IT of over 100 years. We have a good understanding of the current issues in the healthcare space, and have a clear vision for our product. Our initial aim was to improve current administrative functions in General Practice. A 16,000 patient practice in Wales issues approximately 450,000 repeat prescription items per year. The process is paper-bases and prescriptions are handled manually. This necessitates two full time administrators dedicated solely for this role, costing £34,000 p/a and often there is overspill into GP appointments resulting in 11% of GP time spent on administrative tasks, this results in scarce resources being allocated to unnecessary tasks. We developed an agnostic digital platform allowing real-time interaction with the patient care record to digitalise this process allowing for reallocation of resources. As our solution has progressed, we have begun to realise the wider application of our platform to act as conduit allowing digital systems integration between the myriad of isolated systems used by healthcare providers and improve access, functionality and transparency for patients promoting and enabling self-driven and decentralised healthcare. We have currently developed a high-fidelity prototype, which we intend to initially deploy within our own organisation (a group GP practice of 28,000 patients) and are working with Cwm Taf Morgannwg UHB who have provided us a letter of interest in our solution. We seek funding to take our solution from prototype to Minimum Viable Product where we intend initially implement it locally, before expanding both regionally and nationally. We are currently based in Aberdare and given our solution is highly scalable it would provide local economic benefit by creating a number of health technology employment opportunities in the region. | Missing/Incomplete | 0business_rnd_innovation
|
gen_bb1d83c00f45be083c49db624cc9cca2 | A coordinated strategy to scale-up advanced therapies for patient in Manchester | Innovate UK | The Christie NHS Foundation Trust | HRCS22_21929 | Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details. | Infrastructure | 7research_infrastructure
|
gen_71cba5f8f49a867cd75d9c0f1f975d67 | Personalised health: from the inside out | Innovate UK | The Gut Feeling (Tgf) Limited | HRCS22_21936 | 40% of the population suffers from a gastrointestinal disorder (predominantly IBS, IBD, chronic constipation and bloating) and there is no known cure. The topic is unapproachable and taboo (_people don't talk about their bowel movements and poo!_), and no brand has tried to pull down those barriers and empower conversation. People are often unable to get the support they need through the NHS due to lack of expertise and long wait times. Just over 50% are referred to Gastroenterology within five months and other pathways are similarly long waits. Private options such as consulting a Dietitian start at £100 per appointment, and usually require a minimum of three sessions. This is where The Gut Feeling (TGF) comes in. We're driven by personal experience of living with gastrointestinal disorders and finding inadequate inaccessible solutions. For this project, we will focus on Irritable Bowel Syndrome (IBS) type symptoms which affects 15% of the population. We are developing a non-diet-based approach for IBS relief which is just as effective as the FODMAP elimination diet approach but with smart technology, rather than costly consultations. TGF's project is the synergy of a simple app, in-house algorithms designed by our experts, and a DAM (digital asset marketplace) of evidence-based wellness approaches and educational content created in collaboration with certified health experts and clinicians. Sprinkle on a bit of tracking and automagic, and this is _a really gutsy move_. How does it work? Based upon an individual's symptoms we generate a personalised plan made up of specialised wellness techniques and educational content for each member. Through simple tracking of digestive health we start to reduce stress, increase circulation, and promote better physical movement and motility of the gastrointestinal (GI) tract. Through this project we will have a tangible app to begin generating revenue from and secure further funding. Eventually we plan to integrate with microbiome tests, enabling people to observe how their diet and holistic interventions affects their gut health and even certain disease risks. The gut is home to 95% of the body's serotonin which regulates mood, sleep and appetite (APA). By helping reduce overactivity of the sympathetic nervous system, the stress system of your body, and armed with the knowledge that 70% of our immune system resides in the gut (UCLA), we will use digital solutions to help people take control, and prevent many health issues from the inside out. | Missing/Incomplete | 0business_rnd_innovation
|
gen_7460264c8d24147d118033f7776a98be | Thyia: putting cervical cancer screening in the hands of women | Innovate UK | Thyia Ltd | HRCS22_21957 | 3200 women and people with cervices are diagnosed with cervical cancer every year in the UK. That's nine women; mothers, daughters, wives, girlfriends, and friends, every day. Sadly, 99% of these cervical cancers are preventable with simple cervical cancer screening. But 1 in 3 women doesn't attend cervical screening. Of these women, they are disproportionately young, from minority ethnic groups, and/or disadvantaged backgrounds. This is increasing health inequalities across the country. But why don't women attend cervical cancer screening? The NHS cervical screening program doesn't serve women's needs or fit their lifestyles. The one size fits all model of NHS cervical screening does not provide a service that women want. The status quo of face-to-face clinic appointments with an intimate cervical smear is embarrassing, time-consuming, and often uncomfortable. Women want a screening program that is convenient, discrete, and comfortable, at home and in their hands. That is why we have created Thyia, to empower women's healthcare. At Thyia, we believe in a world thriving with healthy women that have their healthcare in their hands. To deliver this dream, we are creating an online service providing women with an at-home self-test screening package. This will enable women to have a convenient, discrete, and comfortable cervical cancer screening experience. At Thyia we listen to women. Using their personal experiences we are building a service bespoke to the needs of every woman. We believe our dream, process, and experience can provide women with the freedom to access cervical cancer screening and healthcare on their terms and on their time. This will protect thousands of women from cervical cancer every year. | Missing/Incomplete | 0business_rnd_innovation
|
gen_68cffae0ca8388f205378c94a15e12d3 | Measurement validation of novel nuclear-targeting DNA as next generation therapies | Innovate UK | Touchlight Ip Limited | HRCS22_21961 | With the development of new DNA-based therapies and technologies the demand for nucleic acid products continues to increase. The requirement for large quantities of high-quality DNA and the need to produce more difficult sequences for advanced therapeutics have brought the production of DNA to its limits. Current methods of DNA manufacture rely on bacterial fermentation which suffers from both manufacturing capacity issues and low sequence stability during bacterial growth. Touchlight's synthetic biology DNA production process overcomes the current limitation of bacterial fermentation using enzymatic means of production. This _in vitro_ DNA technology is able to produce large-scale, high-quality constructs using a DNA polymerase to amplify DNA templates and a protelomerase to cleave and ligate amplified DNA into minimal cassettes for use in therapeutics and synthetic biology applications. Continuous developments in the process have resulted in both increased capacity and reduced footprint for DNA manufacture alleviating some of the current bottlenecks associated with nucleic acid production Although large advances in this process have been made in DNA manufacturing a greater understanding of how DNA behaves in a cellular context will allow the production of improved DNA products and platform. Touchlight has developed new DNA constructs with improved cellular and nuclear targeting abilities resulting in increased protein expression however the limited knowledge and ability to monitor DNA within a cell makes further optimisation challenging. A more detailed understanding of the DNA subcellular localisation is therefore essential for the continuing improvement of Touchlight's core constructs. The knowledge generated from this project will increase Touchlight's ability to satisfy DNA demand and will contribute directly to improving human health. Translated improvements in nuclear entry efficiency for Touchlight's leading _in vitro_ DNA manufacturing process will help meet the increasing demand of DNA constructs from Industrial partners and decrease the costs of DNA therapeutics. | Missing/Incomplete | 0business_rnd_innovation
|
gen_e7b526b1615bfb563b50d72989fe2a26 | Isometric exercise device with intelligent activity and motion monitoring for healthcare (HealthSwitch) | Innovate UK | Tough Life Products Limited | HRCS22_21962 | It's a fact, only 61.4% of people in England aged 16 and over are 'physically active' and people become less active the older they are. There are several reasons for this, many people find that they physically can't do the exercises they once enjoyed; and for those who have been generally inactive, regardless of age, getting started is not easy and for some it's just too hard and so they give up. In addition, cost and space can limit an individual's access to equipment at home; and gyms and sports centres can be seen as intimidating. This project is to innovate an existing fitness product to target physically inactive people, particularly those who are elderly and those with onset of disease; patients in rehabilitation; and those with restricted mobility. This new devise 'Health Switch' will help users gradually improve their upper-body fitness and bone strength without risk of injury, whilst motivating them through an app so that they can monitor their improvement. Tough Life Products Ltd aim to make a smart exercise device based on the existing 'Switch Fitness' design; and also develop an appropriate app to interpret data into useable performance indicators to motivate users. https://www.switchfitnessuk.com/home/ 'Health Switch' will be able to be use in a seated position, such as a wheelchair; it will work on the principle of isometric, 'time under tension' exercise; so instead of using weights or resistance bands the user will work against their own strength, the more tension they put in, the stronger they get; making it effective and challenging throughout their health improvement, irrespective of gender, age or fitness. | Missing/Incomplete | 0business_rnd_innovation
|
gen_8cb752f36f83c58a087610ddae29e620 | TrialSense Data Guardian: Development of real time automated quality artificial intelligence for decentralised clinical trial data | Innovate UK | TrialsenSE Ltd | HRCS22_21966 | Clinical trials are vital to improving the health of everyone. Delays in clinical trials are common and are hugely costly both financially and to patients who may lose out on potential innovative benefits. One source of delays are due to problems found when checking the quality of data within clinical trials. This is traditionally done after all the data is collected. It can be very difficult to resolve a problem months or years later resulting in significant delays and costs incurred. We have developed an artificial intelligence programme to detect the major causes of these problems in real time as the data is being entered. This has the potential to save hundreds of hours of data checking and correction per clinical trial. We wish to refine and test this further to ensure we can maximise the benefit of this before providing it as a solution for all clinical trials. | Missing/Incomplete | 0business_rnd_innovation
|
gen_b1470c1429f0011450a0bd312965fafe | tumchi - an intuitive personalised nutrition platform. | Innovate UK | Tumchi Limited | HRCS22_21969 | tumchi(r), tai chi for your gut microbiome, is a nutritional science company helping people to balance the impact on their health and the environment. tumchi is a created word from 'tum' or 'tummy' and 'chi' - that is known as the most important energy that a person has, a unique concept originated in Eastern philosophy, systems of medical treatment and self-defence. Inspired by 'chi' and 'ying-yang', tumchi keeps the concept of balance in the centre of its innovation. We are digitising a personalised balanced diet and making it accessible for everyone. Through tumchi, we will enable access to scientifically proven information that will open up access to anybody with a computer or a mobile phone. tumchi combines biology with artificial intelligence to deliver effective help with no serious side effects to support people around the world. Current research findings have enough evidence to suggest that the gut microbiome is a new organ system and is often called our 'second brain'. tumchi helps to achieve a healthy balanced diet which is good for the gut microbiome and that tastes good to you too. tumchi is a platform that uniquely combines microbiome analysis, dietetics, gamification, and machine learning to provide highly reliable food recommendations based on individuals' biology and taste preferences. | Missing/Incomplete | 0business_rnd_innovation
|
gen_8b8191a9f79b815f09d7370940323323 | Automated Orthopaedic Implant Identification through Artificial Intelligence | Innovate UK | Unicorn Medics Limited | HRCS22_21973 | The project aims to automate the process of identifying orthopaedic implants on plain radiographs through artificial intelligence techniques. A software will be developed, wherein, a plain radiograph will be fed and the make and model of the implant will be identified within seconds. The objective of the project lies in bringing a change in clinical practise by better utilisation of resources. Automatic identification of implants can lead to better inventory stock management, and better use of surgical and technical staff's time in contrast to spending hours correctly identifying implants' makes and models. We expect this to be invaluable in every joint replacement hospital, particularly those situated in areas with large migrant populations who may have been previously operated for a Total Knee Arthroplasty/Total Hip Arthroplasty with foreign unfamiliar implants. Alongside, the project looks towards tapping into the unmet need in the NHS to rapidly and accurately diagnose unfamiliar implants in the preoperative phase of revision arthroplasty of knee and hip. This will also allow a significant reduction in overall treatment cost and morbidity. In areas where resources are limited, or the technical staff inexperienced, automatic identification will go a long way in patient care. The software will make orthopaedic surgeons more confident of the type of implant prior to surgery, translating to greater precision intra-op, knowing what type of implant is present. Performance of these automated methods is typically on par with trained surgeons and radiologists, and superior to general practitioners. The most experienced surgeons demonstrated an accuracy of 85.6% in recognising the type of implant. Artificial Intelligence has shown to provide nearly 99% accuracy on an identification task on 12 implant models (from the knee and hip), trained and validated on approximately 2,000 radiographs. However, many of these systems use limited training data and/or only attempt to recognise small numbers of implant types, or confine themselves to validate on one joint. Our aim is to ensure a systematic validation of an implant identification system, with implants prioritised by cost-effectiveness, rarity and joint, on a minimum of 100 examples of each type, based on a quality assured, curated training dataset. The project will be encompassing both upper limb and lower limb X-rays. | Missing/Incomplete | 0business_rnd_innovation
|
gen_bf04d89904363c9f00f94fb96a6c1df2 | Microfluidic Assays for Bacterial Detection (MicroBact) | Innovate UK | University of Bristol | HRCS22_21991 | This project aims to deliver a fast and accurate disposable test for diagnosing bacterial infections. The aim will be achieved through secondment of Dr. Pugh, Senior Research Associate and microfluidics expert at University of Bristol to medtech start-up FluoretiQ. Dr. Pugh will gain key assay development and commercial decision making skills which will enhance his career and benefit University of Bristol in delivering commercially relevant teaching and research. | Missing/Incomplete | 0business_rnd_innovation
|
gen_06bef843b48e3f9985a6153ad7a01290 | The Living Laboratory: driving economic growth in Glasgow through real world implementation of precision medicine | Innovate UK | University of Glasgow | HRCS22_22001 | Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details. | Infrastructure | 7research_infrastructure
|
gen_f2a39981cd68f004ddf9d995d9b06b0e | University of the West of Scotland and Kibble Education and Care Centre | Innovate UK | University of the West of Scotland | HRCS22_22045 | To develop an advanced remote health monitoring and behavioural analysis solution utilising machine vision and artificial intelligence to improve operational efficiency, enhance care provision and generate new revenue streams through commercialisation of resulting IP. | Missing/Incomplete | 6project_grants_public
|
gen_91b9f06174be1860f548ef68be629f00 | Virtual VMIC | Innovate UK | Vaccine Manufacturing and Innovation Centre UK Limited | HRCS22_22046 | Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details. | Infrastructure | 7research_infrastructure
|
gen_1b1b81371bf6e92f945d4bde38b6bfcc | Vaccines Manufacturing and Innovation Centre | Innovate UK | Vaccines Manufacturing and Innovation Centre UK Ltd | HRCS22_22047 | Awaiting Public Project Summary | Infrastructure | 7research_infrastructure
|
gen_df9335bf64adf2a8cebf5e86ab36daa9 | Immersive home-fitness solution using muscle-based haptic wearables | Innovate UK | Valkyrie Industries Limited | HRCS22_22049 | Valkyrie Industries is developing a new immersive home-fitness solution using muscle-based haptic wearables. By exploiting our patent in electro-musclular stimulation (EMS) and experience in virtual reality (VR) content creation, we will deliver a system that brings efficient, personalised and engaging fitness routines to people's homes. The design foundations grant will allow us to carry out in-depth customer research, including a human-centered design of low-cost prototype experiences, engagement with stakeholders, and both user-experience and commercial feasibility research. This project falls under the Design for Cross Sector Immersive Projects, applying immersive technologies, haptics and VR gaming, to fitness and healthcare. Valkyrie Industries, after working with heavy-industry partners, is now focusing its attention on the fitness market. Our patented technology allows sensations of weight and resistance in muscles by applying EMS in VR. Recently, VR became a popular destination for home fitness, with games such as Beat Saber and FitXR reaching revenues in the tens of millions of dollars. Additionally, EMS devices such as Slendertone or Sixpad have been extensively used by both professional and amateur athletes, with a renewed interest growing in recent years. We will combine the efficiency of EMS for muscle training and recovery with gamified VR routines, building upon our experience in VR and haptics. The design foundations grant will allow us to understand the motivations of the fitness users, test our market and validate hypotheses, create various simple prototypes and test them with customers. We will use the double-diamond design process to approach the idea of using VR and haptics for fitness. We will: Discover: run workshops with fitness instructors and gym-goers to understand their preferences for the in-house gym experiences. We will understand different training regimes, how different muscle groups are trained etc. Define which exercises can be potentially ported to VR headsets. Based on the stakeholders' interviews, we will formulate the product requirements, the features of the software and hardware systems, the social aspect of the system etc. Develop simple immersive game prototypes using our proprietary wearable haptic technology, and apply it to different muscle groups. We will create 2-4 different simple experiences Deliver: test those prototypes with our focus groups and stakeholders at Here East, gauging the efficiency and engagement of our technology. By the end of the project, we will understand which direction we should take in our further R&D to bring the product closer to market. | Missing/Incomplete | 0business_rnd_innovation
|
gen_d13322a8e6843d4d2a13e90c573a40be | Clinical & market study setup | Innovate UK | Vision Technologies Ltd | HRCS22_22063 | GiveVision has an innovative solution in the fields of ophthalmic telemonitoring in order to support patients undergoing wet Age-Related Macular Degeneration (wetAMD) therapy. Our solution has the potential to significantly enhance patient outcomes if supplied as a companion monitoring device to patients undergoing Anti-VEGF therapy (gold standard treatment for wetAMD). One of the 3 global leaders in manufacturing Anti-VEGF therapies, proposed to potentially sponsor a pilot study in the APAC region. To take this opportunity forward we propose a visit APAC HQ in Bangkok to conduct a feasibility study and meet the stakeholders to discuss the project's potential, identify the resources needed and engage effectively in collaborative research. | Missing/Incomplete | 0business_rnd_innovation
|
gen_055500fae5476824fa5b0b06ada8434a | Zeal-Lifestyle, a start-up focussed on developing a new generation of desirable and sustainable mobility products, removing the stigma of assistive living products. | Innovate UK | Zeal Lifestyle Ltd | HRCS22_22094 | Zeal-Lifestyle is a start-up focused on developing a new generation of desirable and sustainable mobility products. The first launch will be a fully recyclable 4-wheeled mobility aid, made with Great British design and engineering. The idea is that it will be a piece of kit you are proud to be seen with, it represents strength, agility, and prosperity - debunking all the tired and degrading branding that can be associated with a lot of these products currently on the market. Zeal exists to disrupt the assistive product market, by removing stigma and enhancing lifestyles through better design, engineering, and a personal approach to customer experience. Zeal offers its users: * A distinctive, minimalistic mobility aid, with adaptable, custom features in a variety of colours. * Provides an unrivalled personal, unique customer care and service, and a highly accessible and frictionless online customer experience. * A sustainable approach, ensuring a circular economy across all products. The world's most sustainable assistive living company, with a fully recyclable frame. * A community of users online and through social events. Zeal brings like-minded people together, to celebrate life and remove the stigma associated with using assistive products. | Missing/Incomplete | 0business_rnd_innovation
|
gen_d6e7aa2ab6a3b0d3317a44a5479eab68 | Climate, Harmful Algal Blooms (HABs), and Human Health | Natural Environment Research Council | University of Exeter | HRCS22_22226 | Doctoral Training Partnerships: a range of postgraduate training is funded by the Research Councils. For information on current funding routes, see the common terminology at https://www.ukri.org/apply-for-funding/how-we-fund-studentships/. Training grants may be to one organisation or to a consortia of research organisations. This portal will show the lead organisation only. | Studentships | 1fellowships_scholarships
|
gen_d00a6499215a42a6f180c1fc6715ad9b | Stereochemistry of antimicrobial agents in urban water cycle and its impacts upon the evolution of antimicrobial resistance | Natural Environment Research Council | University of Bath | HRCS22_22227 | Doctoral Training Partnerships: a range of postgraduate training is funded by the Research Councils. For information on current funding routes, see the common terminology at https://www.ukri.org/apply-for-funding/how-we-fund-studentships/. Training grants may be to one organisation or to a consortia of research organisations. This portal will show the lead organisation only. | Studentships | 1fellowships_scholarships
|
gen_cdedc402be034565f3191f25afa54b69 | Designing LED lights that minimise the attraction of potential malaria vectors | Natural Environment Research Council | University of Bristol | HRCS22_22228 | Doctoral Training Partnerships: a range of postgraduate training is funded by the Research Councils. For information on current funding routes, see the common terminology at https://www.ukri.org/apply-for-funding/how-we-fund-studentships/. Training grants may be to one organisation or to a consortia of research organisations. This portal will show the lead organisation only. | Studentships | 1fellowships_scholarships
|
gen_230ec863a32fe0855b27f78c7a0e36b2 | The Living Laboratory | UK Research and Innovation | University of Glasgow | HRCS22_22417 | Not available | Infrastructure | 7research_infrastructure
|
gen_61c1aeef76ee004f344db1ea77ce7cc7 | Infection Innovation Consortium (iiCON) | UK Research and Innovation | Liverpool School of Tropical Medicine | HRCS22_22418 | Not available | Infrastructure | 7research_infrastructure
|
gen_4f8a36782438b7273d4dcedf3505e89d | London Advanced Therapies | Research England | King's College London | HRCS22_22419 | Not available | Infrastructure | 7research_infrastructure
|
gen_e9f3576e6092a84cd476c80f85549ad4 | UK SPINE KE: free flow of knowledge to accelerate innovations in ageing | Research England | University of Oxford | HRCS22_22420 | Not available | Infrastructure | 7research_infrastructure
|
gen_0c4560c1f7206d8946fc6b1b5a053cd3 | SETsquared scale-up programme | Research England | University of Bath | HRCS22_22421 | Not available | Infrastructure | 7research_infrastructure
|
gen_a43ec44cb6eac411dbc6693111ea803e | The Bloomsbury SET: Connecting Capability to Combat the Threat from Infectious Disease and Antimicrobial Resistance | Research England | Royal Veterinary College | HRCS22_22422 | Not available | Infrastructure | 7research_infrastructure
|
gen_bde24fc0b161cb70a9b23814b0f9ea7e | MedTech SuperConnector | Research England | Imperial College London | HRCS22_22423 | Not available | Infrastructure | 7research_infrastructure
|
gen_91509e2819b98b13cb3d70c5a7c4faf7 | Aetiological insights | Research England | University of Exeter | HRCS22_22424 | Not available | Infrastructure | 7research_infrastructure
|
gen_e78315bca945784c02dbeaefc51ae8af | Creative Destruction Lab - Oxford | Research England | University of Oxford | HRCS22_22425 | Not available | Infrastructure | 7research_infrastructure
|
gen_4ab9088e36a4da2682f06bd2c8837ae0 | Design Age Institute | Research England | Royal College of Art | HRCS22_22426 | Not available | Infrastructure | 7research_infrastructure
|
gen_58694b072f36edfef2da55f1a868da2a | Insights North East (INE) | Research England | Newcastle University | HRCS22_22427 | Not available | Infrastructure | 7research_infrastructure
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.